# LLM audit: narrative, model answer, evaluation

Evaluation: `parsed_prediction` is mapped Yes→1, No→0; compared to `label_lipid_disorder` (1 = next visit has lipid disorder). `unparseable` predictions are excluded from metric counts. See `src/evaluation/evaluate_llm_runs.py` and `src/llm/output_parser.py`.

## Mode `zero_shot`

- Results: `data/outputs/mimiciii/llm_zero_shot_results.csv`
- Raw JSON per row: `data/outputs/mimiciii/raw_llm_responses/zero_shot/`
- Rendered prompts (if present): `data/outputs/mimiciii/prompts_used/zero_shot/prompt_<pair_id>.txt`

### pair_id=25

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease; End stage renal disease; Other encephalopathy; Chronic glomerulonephritis in diseases classified elsewhere; Urinary tract infection, site not specified; Acidosis; Unspecified iridocyclitis; Acquired hemolytic anemia, unspecified; Systemic lupus erythematosus; Personal history of venous thrombosis and embolism; Long-term (current) use of anticoagulants; Swelling, mass, or lump in head and neck; Hyperpotassemia; Lump or mass in breast; Thrombocytopenia, unspecified; Hypocalcemia; Disorders of phosphorus metabolism
- Medications prescribed: Ciprofloxacin HCl; D5W; Labetalol; Morphine Sulfate; Prochlorperazine; NIFEdipine CR; HydrALAzine; Calcium Gluconate; Ondansetron; Sodium Bicarbonate; PredniSONE; LeVETiracetam; Guaifenesin; Sodium Polystyrene Sulfonate; Bisacodyl; Docusate Sodium; Senna; Warfarin; Lactulose; Aliskiren; Clonidine Patch 0.3 mg/24 hr; Furosemide; Heparin Flush (10 units/ml); Alteplase; Magnesium Sulfate; Lorazepam; SW; Ciprofloxacin IV
- Procedures performed: None recorded
```

**Model reply** (`raw_response`):

```
Prediction: No

The current visit record does not provide any explicit evidence of a lipid disorder such as hypercholesterolemia, hyperlipidemia, or any other specific lipid metabolism disorder. The diagnoses listed primarily focus on chronic kidney disease, systemic lupus erythematosus, and other unrelated conditions. There is no mention of lipid levels, lipid panel results, or ongoing management of a lipid disorder. Therefore, based on the information provided, it is not reasonable to predict that "Disorders of Lipid Metabolism" will be diagnosed in the patient's next hospital visit.
```

---

### pair_id=648

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hypoxemia; Multiple myeloma, without mention of having achieved remission; Peripheral stem cells replaced by transplant; Pneumonia, organism unspecified; [ICD9-DX:2554]; Antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use; Other postablative hypothyroidism
- Medications prescribed: Hydrocortisone Na Succ.; Hydrocortisone; Neutra-Phos; Furosemide; Ipratropium Bromide Neb; Albuterol 0.083% Neb Soln; Sulfameth/Trimethoprim DS; Insulin; Levofloxacin; Sodium Chloride 0.9%  Flush; SW; Testosterone 2.5mg Patch; Potassium Chloride Replacement (Oncology); Senna; Docusate Sodium; NS; Magnesium Sulfate; Potassium Phosphate; Levothyroxine Sodium; Heparin; Heparin Sodium; D5W; Sodium Bicarbonate; Sulfameth/Trimethoprim; Acetylcysteine 20%; Pantoprazole; Heparin Flush PICC (100 units/ml); Heparin Flush (10 units/ml); PredniSONE
- Procedures performed: Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

The current visit record does not provide any explicit evidence of a lipid disorder such as hypercholesterolemia, hyperlipidemia, or any other specific lipid metabolism disorder. The diagnoses listed, including hypoxemia, multiple myeloma, pneumonia, and hypothyroidism, do not indicate any ongoing management or diagnosis of a lipid disorder. Additionally, the medications prescribed do not include any treatments specifically targeting lipid abnormalities. Therefore, based on the information provided, there is no strong evidence to suggest that "Disorders of Lipid Metabolism" will be diagnosed in the patient's next hospital visit.
```

---

### pair_id=2081

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Lumbosacral spondylosis without myelopathy; [ICD9-DX:5185]; Defibrination syndrome; Scoliosis [and kyphoscoliosis], idiopathic; Coronary atherosclerosis of native coronary artery; Unspecified essential hypertension; Unspecified acquired hypothyroidism; Pure hypercholesterolemia; Aortocoronary bypass status
- Medications prescribed: None recorded
- Procedures performed: Lumbar and lumbosacral fusion of the anterior column, posterior technique; Other exploration and decompression of spinal canal; Continuous invasive mechanical ventilation for less than 96 consecutive hours; Insertion of endotracheal tube
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The current visit record indicates that the patient has been diagnosed with "Pure hypercholesterolemia." This diagnosis is a clear and explicit indication of a lipid disorder, which falls under the category of "Disorders of Lipid Metabolism." Given that this condition is already diagnosed, it is highly likely that it will be coded again in the patient's next hospital visit. The presence of this specific diagnosis provides strong evidence that the patient has an ongoing lipid metabolism disorder that will likely be addressed in future medical evaluations.
```

---

### pair_id=4305

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Methicillin susceptible Staphylococcus aureus septicemia; Intraspinal abscess; Acute respiratory failure; Acute osteomyelitis, other specified sites; Retention of urine, unspecified; Chronic hepatitis C without mention of hepatic coma; Urinary tract infection, site not specified; Cocaine abuse, unspecified; Severe sepsis; Intervertebral disc disorder with myelopathy, cervical region; Dysthymic disorder; Anemia of other chronic disease
- Medications prescribed: Sodium Chloride 0.9%  Flush; Pantoprazole Sodium; Vial; Heparin; Iso-Osmotic Dextrose; Ampicillin Sodium; Vancomycin HCl; NS (Mini Bag Plus); Morphine Sulfate; Acyclovir; Potassium Chl 20 mEq / 1000 mL D5 1/2 NS; D5W; Potassium Chloride; Midazolam HCl; CefTRIAXone; SW; NS; Nafcillin; Docusate Sodium (Liquid); Bisacodyl; Acetaminophen (Liquid); Dexamethasone; Oxycodone-Acetaminophen Elixir; Oxycodone Liquid; Propofol; Albuterol; Insulin; Potassium Chl 40 mEq / 1000 mL D5 1/2 NS; Albuterol 0.083% Neb Soln; Neutra-Phos; Heparin Flush PICC (100 units/ml); Lactulose; Oxycodone (Sustained Release); OxycodONE (Immediate Release); Alteplase (Catheter Clearance); Ciprofloxacin HCl; Ibuprofen; Acetaminophen; Docusate Sodium; Pantoprazole; Hepatitis B Vaccine
- Procedures performed: Other exploration and decompression of spinal canal; Continuous invasive mechanical ventilation for less than 96 consecutive hours; Insertion of endotracheal tube; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

The current visit record does not provide any explicit evidence of a lipid disorder such as hypercholesterolemia, hyperlipidemia, or any other specific lipid metabolism disorder. The diagnoses listed are primarily related to infections, respiratory failure, and other acute conditions, with no mention of lipid abnormalities or ongoing management of such conditions. The medications prescribed also do not indicate any treatment for lipid disorders. Therefore, based on the information provided, there is no strong evidence to suggest that "Disorders of Lipid Metabolism" will be diagnosed in the patient's next hospital visit.
```

---

### pair_id=5346

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Infection and inflammatory reaction due to other vascular device, implant, and graft; Unspecified septicemia; Acute posthemorrhagic anemia; Thrombocytopenia, unspecified; Angiodysplasia of intestine with hemorrhage; Atrial fibrillation; Congestive heart failure, unspecified; Aortocoronary bypass status; Cardiac pacemaker in situ
- Medications prescribed: Vancomycin HCl; Insulin; Epoetin Alfa; Vial; D5W; Potassium Chloride; Bumetanide; Furosemide; Bivalirudin; Lorazepam; Gentamicin; Isotonic Sodium Chloride; Magnesium Sulfate; Magnesium Oxide; Iso-Osmotic Dextrose; Aspirin EC; Meropenem; NS; SW; Dopamine HCl; Adenosine; Ibutilide Fumarate; Sarna Lotion; traZODONE HCl; Warfarin; Imipenem-Cilastatin; Sertraline HCl; Carvedilol; Enalapril Maleate; Ciprofloxacin; Metronidazole; Miconazole Powder 2%; Docusate Sodium; Senna; Atorvastatin; Amiodarone HCl; Acetaminophen; Pantoprazole; Aluminum-Magnesium Hydroxide; Golytely; Potassium Phosphate; Ranitidine; DopAmine; Diphenhydramine HCl; Linezolid
- Procedures performed: Other endoscopy of small intestine; Endoscopic control of gastric or duodenal bleeding; Colonoscopy; Other electric countershock of heart; Diagnostic ultrasound of heart; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

The current visit record does not provide strong and explicit evidence of a lipid disorder being present or actively managed. While the patient is prescribed Atorvastatin, which is a statin used to manage cholesterol levels, there is no indication in the diagnoses or the clinical context that a specific lipid disorder such as hypercholesterolemia or hyperlipidemia has been diagnosed or is being actively treated. The presence of other medical conditions, including cardiovascular issues, does not suffice to predict a future diagnosis of "Disorders of Lipid Metabolism." Therefore, based on the information provided, I predict that "Disorders of Lipid Metabolism" will not be coded in the patient's next hospital visit.
```

---

### pair_id=5618

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Intracerebral hemorrhage; Pneumonia, organism unspecified; Other vascular complications of medical care, not elsewhere classified; Other convulsions; Chronic airway obstruction, not elsewhere classified; Hypopotassemia; Other musculoskeletal symptoms referable to limbs; Unspecified essential hypertension; Pure hypercholesterolemia; Other specified disease of white blood cells; Other specified anemias; Unspecified diseases of blood and blood-forming organs; Lumbago; Personal history of other diseases of circulatory system
- Medications prescribed: NS; Phenytoin Sodium; Morphine Sulfate; Metoprolol; Zolpidem Tartrate; Fluocinonide 0.05% Cream; Insulin; Enalapril Maleate; Diltiazem; NS (Glass Bottle); Lorazepam; Levetiracetam; Clonidine HCl; Vancomycin HCl; Iso-Osmotic Dextrose; HydrOXYzine HCl; Aspirin; Cyclobenzaprine HCl; Verapamil HCl; Amlodipine; Pantoprazole; Haloperidol; Sodium Chloride 0.9%  Flush; Senna; HydrALAZINE HCl; Heparin; Heparin Flush CVL  (100 units/ml); Potassium Chloride; Ibuprofen Suspension; Lansoprazole Oral Suspension; Dextrose 5%; Levofloxacin; NiCARdipine IV; Propofol; Clonidine TTS 2 Patch; Docusate Sodium (Liquid); Calcium Gluconate; Oxycodone-Acetaminophen Elixir; Dexamethasone; Mannitol 20%; Soln.; Fentanyl Citrate; Acetaminophen; Vial; Pantoprazole Sodium; Alteplase (Catheter Clearance); Neutra-Phos; Clonidine TTS 1 Patch; Magnesium Sulfate; SW
- Procedures performed: Continuous invasive mechanical ventilation for 96 consecutive hours or more; Enteral infusion of concentrated nutritional substances; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The current visit record indicates that the patient has been diagnosed with "Pure hypercholesterolemia." This diagnosis is a clear and explicit indication of a lipid disorder, which falls under the category of "Disorders of Lipid Metabolism." Given that this condition is already documented, it is highly likely that it will be coded as a diagnosis in the patient's next hospital visit. The presence of hypercholesterolemia suggests ongoing management and monitoring of lipid levels, which further supports the prediction of a future diagnosis of a lipid metabolism disorder.
```

---

### pair_id=6816

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hyperpotassemia; Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled; Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; End stage renal disease; Other chest pain; Other specified cardiac dysrhythmias; Congestive heart failure, unspecified; Diastolic heart failure, unspecified; Pure hypercholesterolemia; Coronary atherosclerosis of native coronary artery; Diarrhea; Aortocoronary bypass status; Percutaneous transluminal coronary angioplasty status
- Medications prescribed: Morphine Sulfate; Heparin; Aspirin; Sevelamer; Isosorbide Mononitrate (Extended Release); Atorvastatin; Metoprolol; Insulin; Acetaminophen; Amlodipine; D5W; Heparin Sodium; Nitroglycerin; Sodium Chloride 0.9%  Flush
- Procedures performed: Hemodialysis
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The current visit record indicates that the patient has been diagnosed with "Pure hypercholesterolemia," which is a specific lipid disorder. This diagnosis provides strong and explicit evidence of a lipid metabolism disorder. Additionally, the patient is being treated with Atorvastatin, a medication commonly used to manage hypercholesterolemia, further supporting the likelihood of ongoing management of this condition. Given these factors, it is reasonable to predict that "Disorders of Lipid Metabolism" will be coded as a diagnosis in the patient's next hospital visit.
```

---

### pair_id=8330

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: No
- **Verdict**: wrong
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Cerebral embolism with cerebral infarction; End stage renal disease; Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; Hemiplegia, unspecified, affecting unspecified side; Pneumonitis due to inhalation of food or vomitus; Acute respiratory failure; Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled; Aortic valve disorders; Mitral valve disorders; Chronic airway obstruction, not elsewhere classified; Anemia in chronic kidney disease; Other and unspecified hyperlipidemia; Personal history of malignant neoplasm of prostate; Unspecified sleep apnea; Aphasia; Hypotension, unspecified; [ICD9-DX:7806]; Other and unspecified complications of medical care, not elsewhere classified
- Medications prescribed: Bisacodyl; Allopurinol; Heparin; Lanthanum; Senna; NS; Aspirin; Haloperidol; MetRONIDAZOLE (FLagyl); Acetaminophen; Famotidine; Fluticasone Propionate 110mcg; Iso-Osmotic Dextrose; Vancomycin; Ipratropium Bromide MDI; Albuterol; Fentanyl Citrate; Morphine Sulfate; Chlorhexidine Gluconate 0.12% Oral Rinse; Sodium Chloride 0.9%  Flush; Iso-Osmotic Sodium Chloride; Fluticasone-Salmeterol (250/50); D5W; Insulin; Insulin Human Regular; MethylPREDNISolone Sodium Succ; Magnesium Oxide; Potassium Chloride; Captopril; Pantoprazole Sodium; Vial; Miconazole Powder 2%; Influenza Virus Vaccine; Albuterol 0.083% Neb Soln; Atorvastatin; Lansoprazole Oral Disintegrating Tab; Scopolamine Patch; Dextrose 5%; Levofloxacin; Ipratropium Bromide Neb; CefePIME; Docusate Sodium (Liquid); Sodium Polystyrene Sulfonate; PredniSONE; Nephrocaps; PNEUMOcoccal Vac Polyvalent; Cyanocobalamin; FoLIC Acid
- Procedures performed: Temporary tracheostomy; Percutaneous [endoscopic] gastrostomy [PEG]; Diagnostic ultrasound of heart; Enteral infusion of concentrated nutritional substances; Hemodialysis; Bronchoscopy through artificial stoma; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

The current visit record indicates that the patient has "Other and unspecified hyperlipidemia," which suggests a lipid abnormality. However, there is no explicit evidence of a specific lipid disorder diagnosis such as hypercholesterolemia or hyperlipidemia that would lead to a definitive coding of "Disorders of Lipid Metabolism" in the next hospital visit. The presence of hyperlipidemia is noted, but it is categorized as unspecified, which does not meet the criteria for a strong and explicit diagnosis of a lipid disorder. Therefore, without clear evidence of an actively managed or specific lipid disorder, the prediction is "No."
```

---

### pair_id=8843

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Aortic valve disorders; Cellulitis and abscess of trunk; Chronic lymphoid leukemia, without mention of having achieved remission; Acidosis; Cellulitis and abscess of leg, except foot; Other postoperative infection; Other and unspecified infection due to central venous catheter; Coronary atherosclerosis of native coronary artery; Atrial fibrillation; Unspecified essential hypertension; Other iatrogenic hypotension; Other specified procedures as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure; Enlargement of lymph nodes; Methicillin susceptible Staphylococcus aureus in conditions classified elsewhere and of unspecified site; Pure hypercholesterolemia; Hip joint replacement; Asthma, unspecified type, unspecified
- Medications prescribed: Metoprolol; SW; Dextrose 50%; Docusate Sodium; Ranitidine; Aspirin EC; Acetaminophen; Qvar; Amiodarone; Warfarin; Iron Polysaccharides Complex; Psyllium Wafer; Levofloxacin; Magnesium Sulfate; Furosemide; Iso-Osmotic Dextrose; Vancomycin; CeftazIDIME; Bisacodyl; Heparin Flush PICC (100 units/ml); Potassium Chloride; Senna; D5W; Oxycodone-Acetaminophen; Metoclopramide; Insulin Human Regular; Nitroglycerin; Morphine Sulfate; Calcium Gluconate; Albumin 5% (25g / 500mL); Influenza Virus Vaccine; Captopril; Insulin; Sodium Chloride 0.9%  Flush; Atorvastatin; Milk of Magnesia; PNEUMOcoccal Vac Polyvalent; Cyclobenzaprine HCl; Amlodipine; Triamterene; Carvedilol; 1/2 NS; Propofol; Aspirin; Glycopyrrolate; Docusate Sodium (Liquid); Neostigmine; LR; Chlorhexidine Gluconate 0.12% Oral Rinse; Sucralfate
- Procedures performed: Open and other replacement of aortic valve with tissue graft; Double internal mammary-coronary artery bypass; Excisional debridement of wound, infection, or burn; Extracorporeal circulation auxiliary to open heart surgery; Venous catheterization, not elsewhere classified; Diagnostic ultrasound of heart; Other incision with drainage of skin and subcutaneous tissue
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The current visit record indicates that the patient has been diagnosed with "Pure hypercholesterolemia." This diagnosis is a clear and explicit indication of a lipid disorder, which falls under the category of "Disorders of Lipid Metabolism." Given that this condition is documented in the patient's current visit, it is highly likely that it will be coded as a diagnosis in the patient's next hospital visit as well. The presence of hypercholesterolemia suggests ongoing management and monitoring of lipid levels, reinforcing the prediction of a future diagnosis related to lipid metabolism disorders.
```

---

### pair_id=9503

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Septicemia due to pseudomonas; Pressure ulcer, stage IV; Urinary tract infection, site not specified; Sepsis; Neurogenic bladder NOS; Multiple sclerosis; Anemia, unspecified; Dysthymic disorder; Pure hypercholesterolemia; Personal history of malignant neoplasm of esophagus; Autonomic dysreflexia; Streptococcal septicemia; Calculus of kidney; Hyperpotassemia; Pressure ulcer, lower back; Hypopotassemia; Disorders of phosphorus metabolism; Gastrostomy status; Malnutrition of moderate degree
- Medications prescribed: Sterile Water; Pantoprazole; Potassium Chloride; Tobramycin Sulfate; 5% Dextrose; 0.9% Sodium Chloride (Mini Bag Plus); Potassium Chloride (Powder); Meropenem; Paroxetine; Gabapentin; HYDROmorphone (Dilaudid); Ferrous Sulfate; Prochlorperazine; Fentanyl Patch; Acetaminophen; Ondansetron; Vitamin D; Lorazepam; Docusate Sodium (Liquid); Midodrine; Atorvastatin; Lidocaine 5% Patch; Bisacodyl; Heparin; Influenza Virus Vaccine; Senna; Vial; Iso-Osmotic Dextrose; Vancomycin; CefTAZidime; 0.9% Sodium Chloride; Daptomycin; Heparin Flush (10 units/ml); Sodium Chloride 0.9%  Flush; Vitamin A; Zinc Sulfate; Ferrous Sulfate (Liquid); Ascorbic Acid (Liquid); Metoclopramide; Potassium Phosphate; Neutra-Phos; Sodium Polystyrene Sulfonate
- Procedures performed: Venous catheterization, not elsewhere classified; Replacement of nephrostomy tube; Percutaneous pyelogram; Enteral infusion of concentrated nutritional substances
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The current visit record explicitly states that the patient has been diagnosed with "Pure hypercholesterolemia." This diagnosis indicates a specific lipid disorder that falls under the category of "Disorders of Lipid Metabolism." Given that this condition is already documented, it is reasonable to predict that it will be coded as a diagnosis in the patient's next hospital visit, especially since it is an actively managed condition. The presence of hypercholesterolemia provides strong evidence for the likelihood of a future diagnosis of Disorders of Lipid Metabolism.
```

---

### pair_id=10330

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Drug withdrawal; Alkalosis; Opioid type dependence, continuous; Cocaine abuse, unspecified; Chronic hepatitis C without mention of hepatic coma; Bipolar I disorder, most recent episode (or current) unspecified; Lack of housing; Alcohol abuse, unspecified; Unspecified nonpsychotic mental disorder; Sedative, hypnotic or anxiolytic dependence, continuous; Drug-induced mood disorder
- Medications prescribed: Methadone; Diazepam; Multivitamins; FoLIC Acid; Thiamine; Potassium Chloride; 0.9% Sodium Chloride; Calcium Gluconate; Potassium Phosphate; Multivitamin IV; 5% Dextrose; Sodium Chloride 0.9%  Flush; Docusate Sodium; Senna; Ondansetron; Acetaminophen; Quetiapine Fumarate; Ibuprofen; DiCYCLOmine; Methocarbamol; bismuth subsalicy; Artificial Tears
- Procedures performed: None recorded
```

**Model reply** (`raw_response`):

```
Prediction: No

The current visit record does not provide any explicit evidence of a lipid disorder such as hypercholesterolemia, hyperlipidemia, or any other specific lipid metabolism disorder. The diagnoses listed are primarily related to substance dependence, mental health issues, and chronic hepatitis C, none of which directly indicate a lipid metabolism disorder. Additionally, there is no mention of ongoing management or treatment for a lipid disorder, such as lipid panels or specific medications targeting lipid levels. Therefore, based on the information provided, it is reasonable to predict that "Disorders of Lipid Metabolism" will not be diagnosed in the patient's next hospital visit.
```

---

### pair_id=10771

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Polycystic kidney, autosomal dominant; Secondary hyperparathyroidism (of renal origin); Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; Hyposmolality and/or hyponatremia; Congenital cystic disease of liver; Other ascites; Umbilical hernia without mention of obstruction or gangrene; End stage renal disease; Cirrhosis of liver without mention of alcohol; Anemia in chronic kidney disease; Volume depletion, unspecified; Other iatrogenic hypotension; Kidney dialysis as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure
- Medications prescribed: Sodium Chloride; 0.9% Sodium Chloride; Calcium Carbonate; 1/2 NS; Omeprazole; Albumin 5% (25g / 500mL); Levofloxacin; Heparin Flush (5000 Units/mL); Sodium Chloride 0.9%  Flush; Midodrine; Levothyroxine Sodium; Potassium Chloride; Magnesium Sulfate; Lidocaine 1%; Neutra-Phos; Albumin, Human; Bag; HYDROmorphone (Dilaudid); Ondansetron; CefazoLIN; Acetaminophen; D5 1/2NS; NIFEdipine CR; Metoprolol Tartrate; sevelamer HYDROCHLORIDE; Nephrocaps; Docusate Sodium; Heparin; Bisacodyl; Albumin 25% (12.5g / 50mL); Senna
- Procedures performed: Bilateral nephrectomy; Other open umbilical herniorrhaphy
```

**Model reply** (`raw_response`):

```
Prediction: No

The current visit record does not provide any explicit evidence of a "Disorder of Lipid Metabolism." The diagnoses listed primarily focus on renal issues, such as end-stage renal disease and chronic kidney disease, along with other unrelated conditions like cirrhosis and anemia. There is no mention of hyperlipidemia, hypercholesterolemia, or any specific lipid disorder. 

Additionally, while the patient is on various medications, including those for managing other conditions, there is no indication of ongoing management or treatment specifically targeting lipid metabolism disorders. Therefore, based on the information provided, it is reasonable to conclude that a diagnosis of "Disorders of Lipid Metabolism" is unlikely to be coded in the patient's next hospital visit.
```

---

## Mode `zero_shot_plus`

- Results: `data/outputs/mimiciii/llm_zero_shot_plus_results.csv`
- Raw JSON per row: `data/outputs/mimiciii/raw_llm_responses/zero_shot_plus/`
- Rendered prompts (if present): `data/outputs/mimiciii/prompts_used/zero_shot_plus/prompt_<pair_id>.txt`

### pair_id=25

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease; End stage renal disease; Other encephalopathy; Chronic glomerulonephritis in diseases classified elsewhere; Urinary tract infection, site not specified; Acidosis; Unspecified iridocyclitis; Acquired hemolytic anemia, unspecified; Systemic lupus erythematosus; Personal history of venous thrombosis and embolism; Long-term (current) use of anticoagulants; Swelling, mass, or lump in head and neck; Hyperpotassemia; Lump or mass in breast; Thrombocytopenia, unspecified; Hypocalcemia; Disorders of phosphorus metabolism
- Medications prescribed: Ciprofloxacin HCl; D5W; Labetalol; Morphine Sulfate; Prochlorperazine; NIFEdipine CR; HydrALAzine; Calcium Gluconate; Ondansetron; Sodium Bicarbonate; PredniSONE; LeVETiracetam; Guaifenesin; Sodium Polystyrene Sulfonate; Bisacodyl; Docusate Sodium; Senna; Warfarin; Lactulose; Aliskiren; Clonidine Patch 0.3 mg/24 hr; Furosemide; Heparin Flush (10 units/ml); Alteplase; Magnesium Sulfate; Lorazepam; SW; Ciprofloxacin IV
- Procedures performed: None recorded
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning:

1. **Current Diagnoses**: The patient's current diagnoses include several serious conditions such as hypertensive chronic kidney disease, end-stage renal disease, and systemic lupus erythematosus, among others. However, there is no mention of any specific lipid metabolism disorders such as hypercholesterolemia, hyperlipidemia, or any other lipid-related conditions. The absence of these specific diagnoses is critical, as the prediction guidelines emphasize the need for explicit evidence of a lipid disorder.

2. **Medications Prescribed**: The medications listed do not include any lipid-lowering agents such as statins or fibrates, which would indicate an active management of a lipid disorder. While the patient is on a variety of medications for other conditions, the lack of any medication aimed at managing lipid levels suggests that there is no current diagnosis or management plan for a lipid metabolism disorder.

3. **Comorbid Conditions**: Although the patient has several comorbid conditions, including hypertension and chronic kidney disease, these alone do not provide sufficient evidence for a diagnosis of Disorders of Lipid Metabolism. The guidelines specify that general risk factors or associated conditions (like hypertension or cardiovascular diseases) are not adequate for predicting a future diagnosis of lipid disorders.

4. **Procedures Performed**: There are no procedures recorded that would indicate an evaluation or intervention related to lipid metabolism. The absence of any relevant procedures further supports the conclusion that there is no active management or diagnosis of lipid disorders.

5. **Overall Assessment**: Given the lack of explicit evidence of a lipid disorder in the current visit record, including no diagnoses, no relevant medications, and no procedures related to lipid metabolism, it is reasonable to conclude that the patient is unlikely to receive a diagnosis of "Disorders of Lipid Metabolism" in their next hospital visit.

In summary, without clear evidence of a lipid disorder being present or actively managed, the prediction must be "No."
```

---

### pair_id=648

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hypoxemia; Multiple myeloma, without mention of having achieved remission; Peripheral stem cells replaced by transplant; Pneumonia, organism unspecified; [ICD9-DX:2554]; Antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use; Other postablative hypothyroidism
- Medications prescribed: Hydrocortisone Na Succ.; Hydrocortisone; Neutra-Phos; Furosemide; Ipratropium Bromide Neb; Albuterol 0.083% Neb Soln; Sulfameth/Trimethoprim DS; Insulin; Levofloxacin; Sodium Chloride 0.9%  Flush; SW; Testosterone 2.5mg Patch; Potassium Chloride Replacement (Oncology); Senna; Docusate Sodium; NS; Magnesium Sulfate; Potassium Phosphate; Levothyroxine Sodium; Heparin; Heparin Sodium; D5W; Sodium Bicarbonate; Sulfameth/Trimethoprim; Acetylcysteine 20%; Pantoprazole; Heparin Flush PICC (100 units/ml); Heparin Flush (10 units/ml); PredniSONE
- Procedures performed: Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning:

1. **Current Diagnoses**: The patient's current diagnoses include hypoxemia, multiple myeloma, pneumonia, and other conditions, but there is no mention of any specific lipid metabolism disorders such as hypercholesterolemia or hyperlipidemia. The absence of a direct diagnosis related to lipid metabolism is a critical factor in this analysis.

2. **Medications Prescribed**: The medications listed do not include any lipid-lowering agents such as statins or fibrates, which would indicate an active management of a lipid disorder. While the patient is on a variety of medications, none are specifically aimed at addressing lipid levels or disorders.

3. **Comorbid Conditions**: The patient's medical history does not indicate the presence of common comorbid conditions that are typically associated with lipid disorders, such as diabetes mellitus or obesity. While multiple myeloma and other conditions may have indirect effects on metabolism, they do not provide explicit evidence of a lipid disorder.

4. **Procedures Performed**: The procedures performed, such as venous catheterization, do not relate to lipid metabolism or suggest any ongoing management of lipid disorders. There is no indication that the patient has undergone any procedures that would typically be associated with the diagnosis or treatment of lipid metabolism disorders.

5. **Risk Factors**: Although the patient may have risk factors for cardiovascular disease due to their multiple comorbidities, these factors alone do not equate to a diagnosis of a lipid disorder. The guidelines specify that general risk factors are insufficient for predicting a future diagnosis.

6. **Conclusion**: Given the lack of explicit evidence of a lipid disorder in the current visit record, including no diagnoses, no relevant medications, and no associated procedures, it is reasonable to conclude that "Disorders of Lipid Metabolism" will not be coded in the patient's next hospital visit. The prediction is based strictly on the presence or absence of direct evidence of lipid disorders, as outlined in the instructions.

Thus, the final prediction is "No."
```

---

### pair_id=2081

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Lumbosacral spondylosis without myelopathy; [ICD9-DX:5185]; Defibrination syndrome; Scoliosis [and kyphoscoliosis], idiopathic; Coronary atherosclerosis of native coronary artery; Unspecified essential hypertension; Unspecified acquired hypothyroidism; Pure hypercholesterolemia; Aortocoronary bypass status
- Medications prescribed: None recorded
- Procedures performed: Lumbar and lumbosacral fusion of the anterior column, posterior technique; Other exploration and decompression of spinal canal; Continuous invasive mechanical ventilation for less than 96 consecutive hours; Insertion of endotracheal tube
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The patient's current visit record indicates a diagnosis of "Pure hypercholesterolemia." This diagnosis is a clear and explicit indication of a lipid metabolism disorder, which falls under the definition of "Disorders of Lipid Metabolism." The presence of hypercholesterolemia suggests that the patient has an ongoing issue with lipid metabolism that is likely to be managed or monitored in future visits.

In addition to the diagnosis of hypercholesterolemia, the patient has a history of coronary atherosclerosis, which is often associated with lipid disorders. While the presence of cardiovascular diseases alone is not sufficient to predict a future diagnosis of lipid disorders, it does highlight the relevance of lipid management in this patient's overall health.

The absence of prescribed medications in the current visit record does not negate the diagnosis of hypercholesterolemia, as it is possible that the patient may have been previously managed with lifestyle changes or medications that are not recorded in this visit. However, the explicit diagnosis of hypercholesterolemia is strong evidence that the patient is likely to have ongoing management for this condition.

Given that the patient has a documented lipid disorder (hypercholesterolemia), it is reasonable to predict that "Disorders of Lipid Metabolism" will be coded in the patient's next hospital visit, as this condition requires monitoring and may lead to further interventions or management strategies.

In conclusion, the presence of pure hypercholesterolemia provides strong evidence for the prediction of a future diagnosis of "Disorders of Lipid Metabolism."
```

---

### pair_id=4305

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Methicillin susceptible Staphylococcus aureus septicemia; Intraspinal abscess; Acute respiratory failure; Acute osteomyelitis, other specified sites; Retention of urine, unspecified; Chronic hepatitis C without mention of hepatic coma; Urinary tract infection, site not specified; Cocaine abuse, unspecified; Severe sepsis; Intervertebral disc disorder with myelopathy, cervical region; Dysthymic disorder; Anemia of other chronic disease
- Medications prescribed: Sodium Chloride 0.9%  Flush; Pantoprazole Sodium; Vial; Heparin; Iso-Osmotic Dextrose; Ampicillin Sodium; Vancomycin HCl; NS (Mini Bag Plus); Morphine Sulfate; Acyclovir; Potassium Chl 20 mEq / 1000 mL D5 1/2 NS; D5W; Potassium Chloride; Midazolam HCl; CefTRIAXone; SW; NS; Nafcillin; Docusate Sodium (Liquid); Bisacodyl; Acetaminophen (Liquid); Dexamethasone; Oxycodone-Acetaminophen Elixir; Oxycodone Liquid; Propofol; Albuterol; Insulin; Potassium Chl 40 mEq / 1000 mL D5 1/2 NS; Albuterol 0.083% Neb Soln; Neutra-Phos; Heparin Flush PICC (100 units/ml); Lactulose; Oxycodone (Sustained Release); OxycodONE (Immediate Release); Alteplase (Catheter Clearance); Ciprofloxacin HCl; Ibuprofen; Acetaminophen; Docusate Sodium; Pantoprazole; Hepatitis B Vaccine
- Procedures performed: Other exploration and decompression of spinal canal; Continuous invasive mechanical ventilation for less than 96 consecutive hours; Insertion of endotracheal tube; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning:

1. **Current Diagnoses**: The patient's current visit record lists several serious conditions, including septicemia, acute respiratory failure, and chronic hepatitis C. However, there is no mention of any specific lipid metabolism disorders such as hypercholesterolemia, hyperlipidemia, or any related conditions. The absence of these explicit diagnoses is critical, as the prediction guidelines emphasize the need for strong evidence of a lipid disorder.

2. **Medications Prescribed**: The medications listed do not include any lipid-lowering agents such as statins or fibrates, which would indicate an active management of a lipid disorder. While the patient is receiving a variety of treatments for their acute conditions, none of these medications suggest that there is an ongoing treatment for lipid metabolism issues.

3. **Procedures Performed**: The procedures performed during this visit, such as spinal canal decompression and mechanical ventilation, do not directly relate to lipid metabolism or suggest any management of lipid disorders. They are focused on addressing acute medical issues rather than metabolic health.

4. **Risk Factors**: Although the patient has chronic hepatitis C, which can be associated with metabolic syndrome and dyslipidemia, there is no direct evidence in the current visit record that indicates the presence of a lipid disorder. The presence of other comorbidities, such as severe sepsis and urinary tract infection, does not inherently increase the likelihood of a lipid disorder diagnosis in the next visit.

5. **General Clinical Risk**: The guidelines specify that general risk factors (like chronic diseases or the use of certain medications) are not sufficient to predict a future diagnosis of "Disorders of Lipid Metabolism." Therefore, even if the patient is at high risk due to their overall health status, this does not translate into a definitive diagnosis of a lipid disorder.

In conclusion, based on the current visit record, there is no explicit evidence of a lipid metabolism disorder present or being actively managed. Therefore, I predict that "Disorders of Lipid Metabolism" will not be coded in the patient's next hospital visit.
```

---

### pair_id=5346

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Infection and inflammatory reaction due to other vascular device, implant, and graft; Unspecified septicemia; Acute posthemorrhagic anemia; Thrombocytopenia, unspecified; Angiodysplasia of intestine with hemorrhage; Atrial fibrillation; Congestive heart failure, unspecified; Aortocoronary bypass status; Cardiac pacemaker in situ
- Medications prescribed: Vancomycin HCl; Insulin; Epoetin Alfa; Vial; D5W; Potassium Chloride; Bumetanide; Furosemide; Bivalirudin; Lorazepam; Gentamicin; Isotonic Sodium Chloride; Magnesium Sulfate; Magnesium Oxide; Iso-Osmotic Dextrose; Aspirin EC; Meropenem; NS; SW; Dopamine HCl; Adenosine; Ibutilide Fumarate; Sarna Lotion; traZODONE HCl; Warfarin; Imipenem-Cilastatin; Sertraline HCl; Carvedilol; Enalapril Maleate; Ciprofloxacin; Metronidazole; Miconazole Powder 2%; Docusate Sodium; Senna; Atorvastatin; Amiodarone HCl; Acetaminophen; Pantoprazole; Aluminum-Magnesium Hydroxide; Golytely; Potassium Phosphate; Ranitidine; DopAmine; Diphenhydramine HCl; Linezolid
- Procedures performed: Other endoscopy of small intestine; Endoscopic control of gastric or duodenal bleeding; Colonoscopy; Other electric countershock of heart; Diagnostic ultrasound of heart; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning:

1. **Current Diagnoses**: The patient's current visit record lists several diagnoses, including infections, septicemia, anemia, thrombocytopenia, and various cardiovascular conditions (e.g., atrial fibrillation, congestive heart failure). However, there is no mention of any specific lipid metabolism disorders such as hypercholesterolemia, hyperlipidemia, or any other related conditions. The absence of a direct diagnosis related to lipid metabolism is a critical factor in this analysis.

2. **Medications Prescribed**: The patient has been prescribed Atorvastatin, which is a statin used to manage cholesterol levels. However, the mere use of a statin does not provide sufficient evidence to predict a future diagnosis of a lipid disorder. The guidelines explicitly state that the use of statins alone is not enough to warrant a "Yes" prediction. There are no other medications in the list that indicate active management of a lipid disorder.

3. **Procedures Performed**: The procedures performed during this visit include endoscopic interventions and diagnostic tests related to gastrointestinal bleeding and cardiac evaluation. None of these procedures directly relate to the assessment or management of lipid metabolism disorders. 

4. **Comorbid Conditions**: While the patient has several comorbid conditions, including cardiovascular diseases, these alone do not imply the presence of a lipid disorder. The guidelines emphasize that general risk factors such as hypertension or diabetes are not sufficient for predicting a diagnosis of lipid disorders.

5. **Overall Assessment**: Given the lack of explicit evidence of a lipid disorder in the current visit record, including no diagnosis of hyperlipidemia or related conditions, and the reliance on statin therapy without a documented lipid disorder, it is reasonable to conclude that there is insufficient evidence to predict that "Disorders of Lipid Metabolism" will be coded in the patient's next hospital visit.

In summary, the absence of a clear diagnosis of a lipid metabolism disorder, despite the use of a statin, leads to the conclusion that there is no strong evidence to support a future diagnosis of "Disorders of Lipid Metabolism." Therefore, the prediction is "No."
```

---

### pair_id=5618

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Intracerebral hemorrhage; Pneumonia, organism unspecified; Other vascular complications of medical care, not elsewhere classified; Other convulsions; Chronic airway obstruction, not elsewhere classified; Hypopotassemia; Other musculoskeletal symptoms referable to limbs; Unspecified essential hypertension; Pure hypercholesterolemia; Other specified disease of white blood cells; Other specified anemias; Unspecified diseases of blood and blood-forming organs; Lumbago; Personal history of other diseases of circulatory system
- Medications prescribed: NS; Phenytoin Sodium; Morphine Sulfate; Metoprolol; Zolpidem Tartrate; Fluocinonide 0.05% Cream; Insulin; Enalapril Maleate; Diltiazem; NS (Glass Bottle); Lorazepam; Levetiracetam; Clonidine HCl; Vancomycin HCl; Iso-Osmotic Dextrose; HydrOXYzine HCl; Aspirin; Cyclobenzaprine HCl; Verapamil HCl; Amlodipine; Pantoprazole; Haloperidol; Sodium Chloride 0.9%  Flush; Senna; HydrALAZINE HCl; Heparin; Heparin Flush CVL  (100 units/ml); Potassium Chloride; Ibuprofen Suspension; Lansoprazole Oral Suspension; Dextrose 5%; Levofloxacin; NiCARdipine IV; Propofol; Clonidine TTS 2 Patch; Docusate Sodium (Liquid); Calcium Gluconate; Oxycodone-Acetaminophen Elixir; Dexamethasone; Mannitol 20%; Soln.; Fentanyl Citrate; Acetaminophen; Vial; Pantoprazole Sodium; Alteplase (Catheter Clearance); Neutra-Phos; Clonidine TTS 1 Patch; Magnesium Sulfate; SW
- Procedures performed: Continuous invasive mechanical ventilation for 96 consecutive hours or more; Enteral infusion of concentrated nutritional substances; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The patient's current hospital visit record indicates a diagnosis of "Pure hypercholesterolemia." This is a clear and explicit diagnosis of a lipid metabolism disorder, which falls under the target definition of "Disorders of Lipid Metabolism." The presence of this diagnosis strongly supports the likelihood that the patient will have a similar diagnosis coded in their next hospital visit.

In addition to the diagnosis, the patient's medication profile does not include any specific lipid-lowering agents such as statins, which could suggest ongoing management of a lipid disorder. However, the explicit diagnosis of hypercholesterolemia itself is sufficient evidence to predict that "Disorders of Lipid Metabolism" will be present in the next visit.

Furthermore, the patient's medical history includes various comorbid conditions, but none of these alone would warrant a diagnosis of lipid disorders without the explicit evidence already present. The presence of hypercholesterolemia indicates that the patient is already being monitored for lipid levels, which further supports the prediction.

In summary, the clear diagnosis of "Pure hypercholesterolemia" provides strong evidence that the patient will likely have a diagnosis of "Disorders of Lipid Metabolism" in their next hospital visit.
```

---

### pair_id=6816

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hyperpotassemia; Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled; Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; End stage renal disease; Other chest pain; Other specified cardiac dysrhythmias; Congestive heart failure, unspecified; Diastolic heart failure, unspecified; Pure hypercholesterolemia; Coronary atherosclerosis of native coronary artery; Diarrhea; Aortocoronary bypass status; Percutaneous transluminal coronary angioplasty status
- Medications prescribed: Morphine Sulfate; Heparin; Aspirin; Sevelamer; Isosorbide Mononitrate (Extended Release); Atorvastatin; Metoprolol; Insulin; Acetaminophen; Amlodipine; D5W; Heparin Sodium; Nitroglycerin; Sodium Chloride 0.9%  Flush
- Procedures performed: Hemodialysis
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The patient's current hospital visit record provides strong evidence for a diagnosis of "Disorders of Lipid Metabolism" in the next hospital visit. Here’s the detailed reasoning:

1. **Current Diagnoses**: The patient has been diagnosed with "Pure hypercholesterolemia." This is a direct indication of a lipid metabolism disorder, as hypercholesterolemia falls under the definition of Disorders of Lipid Metabolism. The presence of this diagnosis is a strong indicator that the patient is already experiencing a lipid disorder.

2. **Medications Prescribed**: The patient has been prescribed Atorvastatin, which is a statin used to manage cholesterol levels. While the use of statins alone is not sufficient to predict a future diagnosis, in conjunction with the diagnosis of hypercholesterolemia, it indicates that the patient's lipid levels are being actively managed. This further supports the likelihood of a lipid disorder being coded in future visits.

3. **Comorbid Conditions**: The patient has several comorbid conditions, including diabetes and chronic kidney disease. These conditions are often associated with dyslipidemia and can exacerbate lipid metabolism disorders. However, the presence of these conditions alone does not directly lead to a diagnosis of lipid disorders unless there is explicit evidence of lipid abnormalities.

4. **Procedures Performed**: The patient has undergone hemodialysis, which is relevant in the context of chronic kidney disease. While this procedure does not directly relate to lipid metabolism disorders, it indicates a complex medical history that may influence lipid levels and management.

5. **Overall Assessment**: Given the explicit diagnosis of hypercholesterolemia and the management with Atorvastatin, there is clear evidence of an ongoing lipid disorder. The presence of this diagnosis is a strong predictor that it will be coded again in the next hospital visit, as it indicates that the condition is recognized and being treated.

In conclusion, the combination of the diagnosis of hypercholesterolemia and the management with a lipid-lowering medication provides strong evidence that "Disorders of Lipid Metabolism" will be present as a diagnosis in the patient's next hospital visit.
```

---

### pair_id=8330

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Cerebral embolism with cerebral infarction; End stage renal disease; Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; Hemiplegia, unspecified, affecting unspecified side; Pneumonitis due to inhalation of food or vomitus; Acute respiratory failure; Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled; Aortic valve disorders; Mitral valve disorders; Chronic airway obstruction, not elsewhere classified; Anemia in chronic kidney disease; Other and unspecified hyperlipidemia; Personal history of malignant neoplasm of prostate; Unspecified sleep apnea; Aphasia; Hypotension, unspecified; [ICD9-DX:7806]; Other and unspecified complications of medical care, not elsewhere classified
- Medications prescribed: Bisacodyl; Allopurinol; Heparin; Lanthanum; Senna; NS; Aspirin; Haloperidol; MetRONIDAZOLE (FLagyl); Acetaminophen; Famotidine; Fluticasone Propionate 110mcg; Iso-Osmotic Dextrose; Vancomycin; Ipratropium Bromide MDI; Albuterol; Fentanyl Citrate; Morphine Sulfate; Chlorhexidine Gluconate 0.12% Oral Rinse; Sodium Chloride 0.9%  Flush; Iso-Osmotic Sodium Chloride; Fluticasone-Salmeterol (250/50); D5W; Insulin; Insulin Human Regular; MethylPREDNISolone Sodium Succ; Magnesium Oxide; Potassium Chloride; Captopril; Pantoprazole Sodium; Vial; Miconazole Powder 2%; Influenza Virus Vaccine; Albuterol 0.083% Neb Soln; Atorvastatin; Lansoprazole Oral Disintegrating Tab; Scopolamine Patch; Dextrose 5%; Levofloxacin; Ipratropium Bromide Neb; CefePIME; Docusate Sodium (Liquid); Sodium Polystyrene Sulfonate; PredniSONE; Nephrocaps; PNEUMOcoccal Vac Polyvalent; Cyanocobalamin; FoLIC Acid
- Procedures performed: Temporary tracheostomy; Percutaneous [endoscopic] gastrostomy [PEG]; Diagnostic ultrasound of heart; Enteral infusion of concentrated nutritional substances; Hemodialysis; Bronchoscopy through artificial stoma; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning:

1. **Current Diagnoses**: The patient has been diagnosed with "Other and unspecified hyperlipidemia." This diagnosis is a direct indication of a lipid metabolism disorder, as it falls under the broader category of lipid abnormalities. The presence of this diagnosis strongly suggests that the patient has an existing issue with lipid metabolism that is likely to be monitored and managed in future visits.

2. **Medications**: The patient is prescribed Atorvastatin, which is a statin used to manage cholesterol levels. The use of statins is typically associated with the treatment of hyperlipidemia and other lipid disorders. While the guidelines specify that the use of statins alone is not sufficient to predict a future diagnosis, in conjunction with the current diagnosis of hyperlipidemia, it reinforces the likelihood of ongoing management of a lipid disorder.

3. **Comorbid Conditions**: The patient has several comorbid conditions, including diabetes mellitus and chronic kidney disease. Both of these conditions are known risk factors for lipid metabolism disorders. Diabetes, in particular, is often associated with dyslipidemia, which can complicate the management of lipid levels.

4. **Procedures**: The patient has undergone significant medical procedures, including hemodialysis. While hemodialysis itself does not directly indicate a lipid disorder, patients with end-stage renal disease often experience alterations in lipid metabolism, which can lead to dyslipidemia. This further supports the need for ongoing monitoring of lipid levels.

5. **Overall Assessment**: Given the explicit diagnosis of hyperlipidemia, the use of a lipid-lowering medication (Atorvastatin), and the presence of comorbid conditions that are associated with lipid metabolism disorders, there is strong evidence to suggest that the patient will have a diagnosis of "Disorders of Lipid Metabolism" coded in their next hospital visit. The combination of these factors indicates that the patient's lipid levels are likely being actively managed and monitored, which aligns with the criteria for predicting a future diagnosis.

In conclusion, the presence of an existing diagnosis of hyperlipidemia, the use of Atorvastatin, and the patient's comorbid conditions collectively provide strong evidence that "Disorders of Lipid Metabolism" will be present as a diagnosis in the patient's next hospital visit.
```

---

### pair_id=8843

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Aortic valve disorders; Cellulitis and abscess of trunk; Chronic lymphoid leukemia, without mention of having achieved remission; Acidosis; Cellulitis and abscess of leg, except foot; Other postoperative infection; Other and unspecified infection due to central venous catheter; Coronary atherosclerosis of native coronary artery; Atrial fibrillation; Unspecified essential hypertension; Other iatrogenic hypotension; Other specified procedures as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure; Enlargement of lymph nodes; Methicillin susceptible Staphylococcus aureus in conditions classified elsewhere and of unspecified site; Pure hypercholesterolemia; Hip joint replacement; Asthma, unspecified type, unspecified
- Medications prescribed: Metoprolol; SW; Dextrose 50%; Docusate Sodium; Ranitidine; Aspirin EC; Acetaminophen; Qvar; Amiodarone; Warfarin; Iron Polysaccharides Complex; Psyllium Wafer; Levofloxacin; Magnesium Sulfate; Furosemide; Iso-Osmotic Dextrose; Vancomycin; CeftazIDIME; Bisacodyl; Heparin Flush PICC (100 units/ml); Potassium Chloride; Senna; D5W; Oxycodone-Acetaminophen; Metoclopramide; Insulin Human Regular; Nitroglycerin; Morphine Sulfate; Calcium Gluconate; Albumin 5% (25g / 500mL); Influenza Virus Vaccine; Captopril; Insulin; Sodium Chloride 0.9%  Flush; Atorvastatin; Milk of Magnesia; PNEUMOcoccal Vac Polyvalent; Cyclobenzaprine HCl; Amlodipine; Triamterene; Carvedilol; 1/2 NS; Propofol; Aspirin; Glycopyrrolate; Docusate Sodium (Liquid); Neostigmine; LR; Chlorhexidine Gluconate 0.12% Oral Rinse; Sucralfate
- Procedures performed: Open and other replacement of aortic valve with tissue graft; Double internal mammary-coronary artery bypass; Excisional debridement of wound, infection, or burn; Extracorporeal circulation auxiliary to open heart surgery; Venous catheterization, not elsewhere classified; Diagnostic ultrasound of heart; Other incision with drainage of skin and subcutaneous tissue
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The patient's current hospital visit record provides strong evidence for the presence of a "Disorder of Lipid Metabolism" diagnosis in their next hospital visit. Here’s the detailed reasoning:

1. **Current Diagnoses**: Among the diagnoses made during this visit, "Pure hypercholesterolemia" is explicitly noted. This condition falls directly under the definition of Disorders of Lipid Metabolism, which includes hypercholesterolemia as a specific diagnosis. The presence of this diagnosis is a strong indicator that the patient has an existing lipid metabolism disorder.

2. **Medications Prescribed**: The patient has been prescribed Atorvastatin, which is a statin used to manage cholesterol levels. While the use of statins alone is not sufficient to predict a future diagnosis, it does support the management of the already diagnosed hypercholesterolemia. The ongoing treatment with a lipid-lowering medication suggests that the healthcare team is actively addressing the patient's lipid levels.

3. **Comorbid Conditions**: The patient has several comorbid conditions, including coronary atherosclerosis and atrial fibrillation, which are often associated with lipid metabolism disorders. While these conditions alone do not confirm a diagnosis of lipid disorders, they indicate a higher risk profile for cardiovascular issues, which are often linked to dyslipidemia.

4. **Procedures Performed**: The patient underwent significant cardiovascular procedures, including aortic valve replacement and coronary artery bypass grafting. These procedures are often performed in patients with underlying lipid disorders, particularly when there is evidence of atherosclerosis. The surgical history further emphasizes the importance of managing lipid levels to prevent further cardiovascular complications.

5. **Overall Assessment**: Given the explicit diagnosis of hypercholesterolemia, the prescription of Atorvastatin, and the presence of cardiovascular comorbidities, there is a clear and strong basis to predict that "Disorders of Lipid Metabolism" will be coded in the patient's next hospital visit. The management of the lipid disorder is already in place, and the patient's medical history supports the likelihood of continued monitoring and diagnosis of lipid metabolism disorders.

In conclusion, the combination of an explicit diagnosis of hypercholesterolemia, the use of lipid-lowering medication, and the presence of related cardiovascular conditions strongly supports the prediction that the patient will have a diagnosis of "Disorders of Lipid Metabolism" in their next hospital visit.
```

---

### pair_id=9503

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Septicemia due to pseudomonas; Pressure ulcer, stage IV; Urinary tract infection, site not specified; Sepsis; Neurogenic bladder NOS; Multiple sclerosis; Anemia, unspecified; Dysthymic disorder; Pure hypercholesterolemia; Personal history of malignant neoplasm of esophagus; Autonomic dysreflexia; Streptococcal septicemia; Calculus of kidney; Hyperpotassemia; Pressure ulcer, lower back; Hypopotassemia; Disorders of phosphorus metabolism; Gastrostomy status; Malnutrition of moderate degree
- Medications prescribed: Sterile Water; Pantoprazole; Potassium Chloride; Tobramycin Sulfate; 5% Dextrose; 0.9% Sodium Chloride (Mini Bag Plus); Potassium Chloride (Powder); Meropenem; Paroxetine; Gabapentin; HYDROmorphone (Dilaudid); Ferrous Sulfate; Prochlorperazine; Fentanyl Patch; Acetaminophen; Ondansetron; Vitamin D; Lorazepam; Docusate Sodium (Liquid); Midodrine; Atorvastatin; Lidocaine 5% Patch; Bisacodyl; Heparin; Influenza Virus Vaccine; Senna; Vial; Iso-Osmotic Dextrose; Vancomycin; CefTAZidime; 0.9% Sodium Chloride; Daptomycin; Heparin Flush (10 units/ml); Sodium Chloride 0.9%  Flush; Vitamin A; Zinc Sulfate; Ferrous Sulfate (Liquid); Ascorbic Acid (Liquid); Metoclopramide; Potassium Phosphate; Neutra-Phos; Sodium Polystyrene Sulfonate
- Procedures performed: Venous catheterization, not elsewhere classified; Replacement of nephrostomy tube; Percutaneous pyelogram; Enteral infusion of concentrated nutritional substances
```

**Model reply** (`raw_response`):

```
Prediction: Yes

The patient's current hospital visit record provides strong evidence for a diagnosis of "Disorders of Lipid Metabolism" in the next hospital visit. Here’s the detailed reasoning:

1. **Current Diagnoses**: The patient has been diagnosed with "Pure hypercholesterolemia." This is a clear indication of a lipid metabolism disorder, as hypercholesterolemia falls directly under the definition of Disorders of Lipid Metabolism. The presence of this diagnosis is a strong predictor that it will be coded again in future visits.

2. **Medications**: The patient has been prescribed Atorvastatin, which is a statin used to manage cholesterol levels. While the use of statins alone is not sufficient to predict a future diagnosis, in conjunction with the diagnosis of hypercholesterolemia, it indicates that the patient's lipid levels are being actively managed. This further supports the likelihood of a lipid disorder diagnosis being present in the next visit.

3. **Comorbid Conditions**: The patient has multiple comorbidities, including sepsis, urinary tract infection, and multiple sclerosis. While these conditions may complicate the patient's overall health, they do not negate the presence of the lipid disorder. Importantly, the presence of hypercholesterolemia is a significant finding that stands out in the context of the patient's overall health.

4. **Procedures**: The procedures performed during this visit, such as venous catheterization and nephrostomy tube replacement, do not directly relate to lipid metabolism. However, they indicate that the patient is receiving comprehensive medical care, which may include ongoing monitoring of lipid levels.

5. **Risk Factors**: Although the patient has several risk factors for cardiovascular disease (e.g., multiple comorbidities), the explicit diagnosis of hypercholesterolemia is the key factor here. The guidelines specify that general risk factors alone are not sufficient for predicting a future diagnosis, but the presence of a specific lipid disorder diagnosis is.

In conclusion, the explicit diagnosis of "Pure hypercholesterolemia" in the current visit record provides strong evidence that "Disorders of Lipid Metabolism" will be present as a diagnosis in the patient's next hospital visit. Therefore, the prediction is "Yes."
```

---

### pair_id=10330

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Drug withdrawal; Alkalosis; Opioid type dependence, continuous; Cocaine abuse, unspecified; Chronic hepatitis C without mention of hepatic coma; Bipolar I disorder, most recent episode (or current) unspecified; Lack of housing; Alcohol abuse, unspecified; Unspecified nonpsychotic mental disorder; Sedative, hypnotic or anxiolytic dependence, continuous; Drug-induced mood disorder
- Medications prescribed: Methadone; Diazepam; Multivitamins; FoLIC Acid; Thiamine; Potassium Chloride; 0.9% Sodium Chloride; Calcium Gluconate; Potassium Phosphate; Multivitamin IV; 5% Dextrose; Sodium Chloride 0.9%  Flush; Docusate Sodium; Senna; Ondansetron; Acetaminophen; Quetiapine Fumarate; Ibuprofen; DiCYCLOmine; Methocarbamol; bismuth subsalicy; Artificial Tears
- Procedures performed: None recorded
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning:

1. **Current Diagnoses**: The patient's current visit record lists multiple diagnoses, including drug withdrawal, opioid dependence, cocaine abuse, chronic hepatitis C, and various mental health disorders. However, there is no mention of any specific lipid metabolism disorders such as hypercholesterolemia, hyperlipidemia, or any related conditions. The absence of these explicit diagnoses is crucial, as the prediction guidelines emphasize the need for strong evidence of a lipid disorder.

2. **Medications Prescribed**: The medications prescribed during this visit include methadone, diazepam, multivitamins, and several other supportive treatments. Notably, there are no lipid-lowering medications such as statins or fibrates included in the medication list. The presence of such medications would have indicated an active management of a lipid disorder, which is a key factor in predicting a future diagnosis.

3. **Procedures Performed**: The record indicates that no procedures were performed during this visit. Procedures that might relate to lipid metabolism, such as lipid panels or interventions for cardiovascular health, are absent. This further supports the lack of evidence for a lipid disorder.

4. **Risk Factors**: While the patient has several risk factors associated with metabolic disorders, such as substance abuse and chronic hepatitis C, these alone do not constitute a diagnosis of a lipid metabolism disorder. The guidelines specify that general risk factors are insufficient for predicting a future diagnosis.

5. **Comorbid Conditions**: The patient's comorbid conditions primarily focus on mental health and substance use disorders. There is no indication of conditions commonly associated with lipid disorders, such as diabetes or obesity, which could have provided additional context for a potential lipid metabolism issue.

6. **Conclusion**: Given the absence of any explicit evidence of a lipid disorder in the current visit record, including diagnoses, medications, and procedures, I conclude that there is no strong basis to predict that "Disorders of Lipid Metabolism" will be diagnosed in the patient's next hospital visit. The prediction guidelines clearly state that a diagnosis must be present or actively managed to warrant a "Yes" response, which is not the case here.

Therefore, the final prediction is "No."
```

---

### pair_id=10771

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Polycystic kidney, autosomal dominant; Secondary hyperparathyroidism (of renal origin); Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; Hyposmolality and/or hyponatremia; Congenital cystic disease of liver; Other ascites; Umbilical hernia without mention of obstruction or gangrene; End stage renal disease; Cirrhosis of liver without mention of alcohol; Anemia in chronic kidney disease; Volume depletion, unspecified; Other iatrogenic hypotension; Kidney dialysis as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure
- Medications prescribed: Sodium Chloride; 0.9% Sodium Chloride; Calcium Carbonate; 1/2 NS; Omeprazole; Albumin 5% (25g / 500mL); Levofloxacin; Heparin Flush (5000 Units/mL); Sodium Chloride 0.9%  Flush; Midodrine; Levothyroxine Sodium; Potassium Chloride; Magnesium Sulfate; Lidocaine 1%; Neutra-Phos; Albumin, Human; Bag; HYDROmorphone (Dilaudid); Ondansetron; CefazoLIN; Acetaminophen; D5 1/2NS; NIFEdipine CR; Metoprolol Tartrate; sevelamer HYDROCHLORIDE; Nephrocaps; Docusate Sodium; Heparin; Bisacodyl; Albumin 25% (12.5g / 50mL); Senna
- Procedures performed: Bilateral nephrectomy; Other open umbilical herniorrhaphy
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning:

1. **Current Diagnoses**: The patient has a complex medical history with multiple diagnoses, including chronic kidney disease (stage V), cirrhosis of the liver, and secondary hyperparathyroidism. None of these conditions explicitly indicate a diagnosis of a lipid metabolism disorder such as hyperlipidemia or hypercholesterolemia. 

2. **Medications**: The medication list does not include any lipid-lowering agents such as statins or fibrates, which would suggest active management of a lipid disorder. While the patient is prescribed medications for various conditions, none are specifically aimed at addressing lipid metabolism.

3. **Procedures**: The patient underwent significant surgical procedures, including bilateral nephrectomy and umbilical herniorrhaphy. These procedures are primarily related to kidney function and do not directly correlate with the diagnosis of lipid metabolism disorders.

4. **Risk Factors**: Although the patient has chronic kidney disease and cirrhosis, which can be associated with dyslipidemia, there is no direct evidence of a lipid disorder in the current visit record. The presence of chronic kidney disease can lead to alterations in lipid metabolism, but without a documented diagnosis of a lipid disorder or active management of such a condition, this alone is insufficient to predict a future diagnosis.

5. **General Risk Factors**: The patient has several comorbid conditions, including hypertension and chronic kidney disease, which are risk factors for cardiovascular disease and potentially for lipid disorders. However, as per the guidelines, these risk factors alone do not warrant a prediction of a diagnosis of "Disorders of Lipid Metabolism" in the next visit.

6. **Conclusion**: Given the absence of explicit evidence of a lipid disorder in the current visit record, including no documented diagnosis or treatment for lipid abnormalities, the prediction is that "Disorders of Lipid Metabolism" will not be coded in the patient's next hospital visit. 

Thus, the final prediction is "No".
```

---

## Mode `few_shot`

- Results: `data/outputs/mimiciii/llm_few_shot_results.csv`
- Raw JSON per row: `data/outputs/mimiciii/raw_llm_responses/few_shot/`
- Rendered prompts (if present): `data/outputs/mimiciii/prompts_used/few_shot/prompt_<pair_id>.txt`

### pair_id=25

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease; End stage renal disease; Other encephalopathy; Chronic glomerulonephritis in diseases classified elsewhere; Urinary tract infection, site not specified; Acidosis; Unspecified iridocyclitis; Acquired hemolytic anemia, unspecified; Systemic lupus erythematosus; Personal history of venous thrombosis and embolism; Long-term (current) use of anticoagulants; Swelling, mass, or lump in head and neck; Hyperpotassemia; Lump or mass in breast; Thrombocytopenia, unspecified; Hypocalcemia; Disorders of phosphorus metabolism
- Medications prescribed: Ciprofloxacin HCl; D5W; Labetalol; Morphine Sulfate; Prochlorperazine; NIFEdipine CR; HydrALAzine; Calcium Gluconate; Ondansetron; Sodium Bicarbonate; PredniSONE; LeVETiracetam; Guaifenesin; Sodium Polystyrene Sulfonate; Bisacodyl; Docusate Sodium; Senna; Warfarin; Lactulose; Aliskiren; Clonidine Patch 0.3 mg/24 hr; Furosemide; Heparin Flush (10 units/ml); Alteplase; Magnesium Sulfate; Lorazepam; SW; Ciprofloxacin IV
- Procedures performed: None recorded
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: 

In analyzing the patient's current hospital visit record, we observe a complex medical history with multiple diagnoses, including hypertensive chronic kidney disease, end-stage renal disease, and systemic lupus erythematosus, among others. However, there is no explicit mention of any disorders related to lipid metabolism, such as hypercholesterolemia, hyperlipidemia, or any other lipid abnormalities.

The medications prescribed during this visit include a variety of drugs, but none are specifically aimed at managing lipid levels or treating lipid disorders. While the patient is on medications like Labetalol and Nifedipine, which are used for hypertension, and Furosemide, which is a diuretic, these do not provide evidence of an active management of lipid disorders. The presence of statins or other lipid-modifying agents is crucial for predicting a future diagnosis of lipid metabolism disorders, and their absence here is significant.

Additionally, the patient's comorbid conditions, while they may contribute to an increased risk of developing lipid disorders, do not in themselves confirm the presence of such disorders. The patient's history of hypertension and chronic kidney disease could potentially influence lipid metabolism, but again, without a documented diagnosis or treatment for a lipid disorder, we cannot conclude that "Disorders of Lipid Metabolism" will be coded in the next visit.

Given the lack of explicit evidence of a lipid disorder in the current visit record, the prediction is that "Disorders of Lipid Metabolism" will not be present in the patient's next hospital visit.
```

---

### pair_id=648

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hypoxemia; Multiple myeloma, without mention of having achieved remission; Peripheral stem cells replaced by transplant; Pneumonia, organism unspecified; [ICD9-DX:2554]; Antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use; Other postablative hypothyroidism
- Medications prescribed: Hydrocortisone Na Succ.; Hydrocortisone; Neutra-Phos; Furosemide; Ipratropium Bromide Neb; Albuterol 0.083% Neb Soln; Sulfameth/Trimethoprim DS; Insulin; Levofloxacin; Sodium Chloride 0.9%  Flush; SW; Testosterone 2.5mg Patch; Potassium Chloride Replacement (Oncology); Senna; Docusate Sodium; NS; Magnesium Sulfate; Potassium Phosphate; Levothyroxine Sodium; Heparin; Heparin Sodium; D5W; Sodium Bicarbonate; Sulfameth/Trimethoprim; Acetylcysteine 20%; Pantoprazole; Heparin Flush PICC (100 units/ml); Heparin Flush (10 units/ml); PredniSONE
- Procedures performed: Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: 

In analyzing the patient's current hospital visit record, we observe the following key points:

1. **Diagnoses Made**: The patient has multiple serious conditions, including hypoxemia, multiple myeloma, pneumonia, and postablative hypothyroidism. However, there is no mention of any specific lipid metabolism disorders such as hypercholesterolemia, hyperlipidemia, or any related conditions.

2. **Medications Prescribed**: The medication list includes a variety of drugs primarily aimed at managing the patient's acute conditions and cancer treatment. Notably, there are no medications that are specifically used for managing lipid disorders, such as statins or fibrates. The presence of medications like hydrocortisone and furosemide does not indicate any active management of lipid levels.

3. **Procedures Performed**: The only procedure listed is venous catheterization, which does not relate to lipid metabolism or indicate any ongoing management of lipid disorders.

4. **Risk Factors**: While the patient has multiple comorbidities, including cancer and pneumonia, these do not directly correlate with a diagnosis of lipid metabolism disorders. The presence of conditions like multiple myeloma and pneumonia does not inherently increase the likelihood of a lipid disorder diagnosis in the next visit.

5. **Absence of Evidence**: The critical factor in this analysis is the absence of any explicit evidence of a lipid disorder in the current visit. The guidelines specify that a "Yes" prediction can only be made if there is strong and explicit evidence of a lipid disorder, which is not present in this case.

Given these points, the conclusion is that there is no indication of a "Disorders of Lipid Metabolism" diagnosis being present in the patient's next hospital visit. Therefore, the prediction is "No".
```

---

### pair_id=2081

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Lumbosacral spondylosis without myelopathy; [ICD9-DX:5185]; Defibrination syndrome; Scoliosis [and kyphoscoliosis], idiopathic; Coronary atherosclerosis of native coronary artery; Unspecified essential hypertension; Unspecified acquired hypothyroidism; Pure hypercholesterolemia; Aortocoronary bypass status
- Medications prescribed: None recorded
- Procedures performed: Lumbar and lumbosacral fusion of the anterior column, posterior technique; Other exploration and decompression of spinal canal; Continuous invasive mechanical ventilation for less than 96 consecutive hours; Insertion of endotracheal tube
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning: The patient's current visit record indicates a diagnosis of "Pure hypercholesterolemia." This diagnosis is a clear and explicit indication of a lipid metabolism disorder, which falls under the category of "Disorders of Lipid Metabolism." The presence of this diagnosis suggests that the patient has an ongoing issue with lipid metabolism that is likely to be monitored and managed in future visits.

In addition to the diagnosis, the patient's medical history includes several comorbid conditions such as coronary atherosclerosis and unspecified essential hypertension, which are often associated with lipid disorders. However, the key factor here is the explicit diagnosis of hypercholesterolemia, which directly supports the prediction of a future diagnosis of Disorders of Lipid Metabolism.

Given that the patient has a documented lipid disorder, it is reasonable to conclude that this condition will be coded again in the next hospital visit, as it is an active and relevant part of their medical history. Therefore, the prediction is that "Disorders of Lipid Metabolism" will indeed be present in the patient's next hospital visit.
```

---

### pair_id=4305

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Methicillin susceptible Staphylococcus aureus septicemia; Intraspinal abscess; Acute respiratory failure; Acute osteomyelitis, other specified sites; Retention of urine, unspecified; Chronic hepatitis C without mention of hepatic coma; Urinary tract infection, site not specified; Cocaine abuse, unspecified; Severe sepsis; Intervertebral disc disorder with myelopathy, cervical region; Dysthymic disorder; Anemia of other chronic disease
- Medications prescribed: Sodium Chloride 0.9%  Flush; Pantoprazole Sodium; Vial; Heparin; Iso-Osmotic Dextrose; Ampicillin Sodium; Vancomycin HCl; NS (Mini Bag Plus); Morphine Sulfate; Acyclovir; Potassium Chl 20 mEq / 1000 mL D5 1/2 NS; D5W; Potassium Chloride; Midazolam HCl; CefTRIAXone; SW; NS; Nafcillin; Docusate Sodium (Liquid); Bisacodyl; Acetaminophen (Liquid); Dexamethasone; Oxycodone-Acetaminophen Elixir; Oxycodone Liquid; Propofol; Albuterol; Insulin; Potassium Chl 40 mEq / 1000 mL D5 1/2 NS; Albuterol 0.083% Neb Soln; Neutra-Phos; Heparin Flush PICC (100 units/ml); Lactulose; Oxycodone (Sustained Release); OxycodONE (Immediate Release); Alteplase (Catheter Clearance); Ciprofloxacin HCl; Ibuprofen; Acetaminophen; Docusate Sodium; Pantoprazole; Hepatitis B Vaccine
- Procedures performed: Other exploration and decompression of spinal canal; Continuous invasive mechanical ventilation for less than 96 consecutive hours; Insertion of endotracheal tube; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" being diagnosed or actively managed. The diagnoses made during this visit include serious conditions such as septicemia, acute respiratory failure, and chronic hepatitis C, but none of these directly indicate a lipid metabolism disorder. 

The medications prescribed do not include any lipid-lowering agents such as statins or fibrates, which would suggest an ongoing management of a lipid disorder. While the patient is on a variety of medications for other conditions, none are specifically aimed at addressing lipid levels or disorders. 

Additionally, the presence of comorbid conditions that are commonly associated with lipid disorders, such as diabetes or obesity, is not mentioned in the record. The absence of any mention of hyperlipidemia, hypercholesterolemia, or any related lipid abnormalities further supports the conclusion that there is no current evidence of a lipid metabolism disorder.

Given these factors, the prediction is that "Disorders of Lipid Metabolism" will not be present as a diagnosis in the patient's next hospital visit.
```

---

### pair_id=5346

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Infection and inflammatory reaction due to other vascular device, implant, and graft; Unspecified septicemia; Acute posthemorrhagic anemia; Thrombocytopenia, unspecified; Angiodysplasia of intestine with hemorrhage; Atrial fibrillation; Congestive heart failure, unspecified; Aortocoronary bypass status; Cardiac pacemaker in situ
- Medications prescribed: Vancomycin HCl; Insulin; Epoetin Alfa; Vial; D5W; Potassium Chloride; Bumetanide; Furosemide; Bivalirudin; Lorazepam; Gentamicin; Isotonic Sodium Chloride; Magnesium Sulfate; Magnesium Oxide; Iso-Osmotic Dextrose; Aspirin EC; Meropenem; NS; SW; Dopamine HCl; Adenosine; Ibutilide Fumarate; Sarna Lotion; traZODONE HCl; Warfarin; Imipenem-Cilastatin; Sertraline HCl; Carvedilol; Enalapril Maleate; Ciprofloxacin; Metronidazole; Miconazole Powder 2%; Docusate Sodium; Senna; Atorvastatin; Amiodarone HCl; Acetaminophen; Pantoprazole; Aluminum-Magnesium Hydroxide; Golytely; Potassium Phosphate; Ranitidine; DopAmine; Diphenhydramine HCl; Linezolid
- Procedures performed: Other endoscopy of small intestine; Endoscopic control of gastric or duodenal bleeding; Colonoscopy; Other electric countershock of heart; Diagnostic ultrasound of heart; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: 

In analyzing the patient's current hospital visit record, we note the following key points:

1. **Diagnoses Made**: The patient has several serious conditions, including infections, septicemia, anemia, thrombocytopenia, and cardiovascular issues (atrial fibrillation and congestive heart failure). However, there is no mention of any specific lipid metabolism disorders such as hypercholesterolemia or hyperlipidemia.

2. **Medications Prescribed**: The patient is prescribed Atorvastatin, which is a statin used to manage cholesterol levels. However, the mere presence of a statin does not provide sufficient evidence of an active diagnosis of a lipid disorder. Statins can be prescribed for various reasons, including primary prevention in high-risk patients, and their use alone does not confirm an existing diagnosis of a lipid metabolism disorder.

3. **Procedures Performed**: The procedures listed, such as endoscopy and colonoscopy, do not directly relate to lipid metabolism or indicate any ongoing management of lipid disorders.

4. **Comorbid Conditions**: While the patient has cardiovascular conditions, which are often associated with lipid disorders, there is no explicit evidence of a diagnosed lipid disorder in the current visit. The presence of cardiovascular diseases alone is not sufficient to predict a future diagnosis of lipid metabolism disorders.

5. **Risk Factors**: The patient has multiple comorbidities, but without a documented history of lipid disorders or specific management of such conditions, we cannot conclude that a diagnosis will be made in the next visit.

Given these points, there is a lack of strong and explicit evidence indicating that a diagnosis of "Disorders of Lipid Metabolism" will be coded in the patient's next hospital visit. Therefore, the prediction is "No".
```

---

### pair_id=5618

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Intracerebral hemorrhage; Pneumonia, organism unspecified; Other vascular complications of medical care, not elsewhere classified; Other convulsions; Chronic airway obstruction, not elsewhere classified; Hypopotassemia; Other musculoskeletal symptoms referable to limbs; Unspecified essential hypertension; Pure hypercholesterolemia; Other specified disease of white blood cells; Other specified anemias; Unspecified diseases of blood and blood-forming organs; Lumbago; Personal history of other diseases of circulatory system
- Medications prescribed: NS; Phenytoin Sodium; Morphine Sulfate; Metoprolol; Zolpidem Tartrate; Fluocinonide 0.05% Cream; Insulin; Enalapril Maleate; Diltiazem; NS (Glass Bottle); Lorazepam; Levetiracetam; Clonidine HCl; Vancomycin HCl; Iso-Osmotic Dextrose; HydrOXYzine HCl; Aspirin; Cyclobenzaprine HCl; Verapamil HCl; Amlodipine; Pantoprazole; Haloperidol; Sodium Chloride 0.9%  Flush; Senna; HydrALAZINE HCl; Heparin; Heparin Flush CVL  (100 units/ml); Potassium Chloride; Ibuprofen Suspension; Lansoprazole Oral Suspension; Dextrose 5%; Levofloxacin; NiCARdipine IV; Propofol; Clonidine TTS 2 Patch; Docusate Sodium (Liquid); Calcium Gluconate; Oxycodone-Acetaminophen Elixir; Dexamethasone; Mannitol 20%; Soln.; Fentanyl Citrate; Acetaminophen; Vial; Pantoprazole Sodium; Alteplase (Catheter Clearance); Neutra-Phos; Clonidine TTS 1 Patch; Magnesium Sulfate; SW
- Procedures performed: Continuous invasive mechanical ventilation for 96 consecutive hours or more; Enteral infusion of concentrated nutritional substances; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning: 

In the patient's current visit record, the diagnosis of "Pure hypercholesterolemia" is explicitly noted. This diagnosis falls under the category of "Disorders of Lipid Metabolism," which includes conditions such as hypercholesterolemia, hyperlipidemia, and related lipid abnormalities. The presence of this diagnosis indicates that the patient has a recognized lipid metabolism disorder that is likely to be actively managed or monitored.

The patient's medication list does not include any specific lipid-lowering agents like statins, which could suggest ongoing management of lipid levels; however, the diagnosis itself is a strong indicator of a lipid disorder. The presence of hypercholesterolemia alone is sufficient evidence to predict that "Disorders of Lipid Metabolism" will be coded in the patient's next hospital visit.

Additionally, the patient's other diagnoses and medical history do not provide any conflicting information that would suggest a resolution or absence of the lipid disorder. Therefore, based on the explicit diagnosis of hypercholesterolemia, it is reasonable to conclude that the patient will have "Disorders of Lipid Metabolism" diagnosed in their next hospital visit.
```

---

### pair_id=6816

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hyperpotassemia; Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled; Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; End stage renal disease; Other chest pain; Other specified cardiac dysrhythmias; Congestive heart failure, unspecified; Diastolic heart failure, unspecified; Pure hypercholesterolemia; Coronary atherosclerosis of native coronary artery; Diarrhea; Aortocoronary bypass status; Percutaneous transluminal coronary angioplasty status
- Medications prescribed: Morphine Sulfate; Heparin; Aspirin; Sevelamer; Isosorbide Mononitrate (Extended Release); Atorvastatin; Metoprolol; Insulin; Acetaminophen; Amlodipine; D5W; Heparin Sodium; Nitroglycerin; Sodium Chloride 0.9%  Flush
- Procedures performed: Hemodialysis
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning: 

In the patient's current visit record, there is a clear diagnosis of "Pure hypercholesterolemia." This diagnosis is a direct indication of a lipid metabolism disorder, which falls under the category of "Disorders of Lipid Metabolism." The presence of this diagnosis is strong evidence that the patient has an existing lipid disorder.

Additionally, the patient is prescribed Atorvastatin, a medication commonly used to manage cholesterol levels, which further supports the active management of a lipid disorder. The combination of the diagnosis of hypercholesterolemia and the prescription of a statin indicates that the patient's lipid levels are being monitored and treated, which is a critical factor in predicting future diagnoses related to lipid metabolism.

While the patient has several comorbid conditions, including diabetes and chronic kidney disease, these do not negate the presence of the diagnosed lipid disorder. Instead, they may contribute to the complexity of the patient's overall health but do not detract from the explicit evidence of a lipid metabolism disorder.

Given the strong and explicit evidence of hypercholesterolemia and the ongoing management with Atorvastatin, it is reasonable to predict that "Disorders of Lipid Metabolism" will be present as a diagnosis in the patient's next hospital visit.
```

---

### pair_id=8330

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Cerebral embolism with cerebral infarction; End stage renal disease; Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; Hemiplegia, unspecified, affecting unspecified side; Pneumonitis due to inhalation of food or vomitus; Acute respiratory failure; Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled; Aortic valve disorders; Mitral valve disorders; Chronic airway obstruction, not elsewhere classified; Anemia in chronic kidney disease; Other and unspecified hyperlipidemia; Personal history of malignant neoplasm of prostate; Unspecified sleep apnea; Aphasia; Hypotension, unspecified; [ICD9-DX:7806]; Other and unspecified complications of medical care, not elsewhere classified
- Medications prescribed: Bisacodyl; Allopurinol; Heparin; Lanthanum; Senna; NS; Aspirin; Haloperidol; MetRONIDAZOLE (FLagyl); Acetaminophen; Famotidine; Fluticasone Propionate 110mcg; Iso-Osmotic Dextrose; Vancomycin; Ipratropium Bromide MDI; Albuterol; Fentanyl Citrate; Morphine Sulfate; Chlorhexidine Gluconate 0.12% Oral Rinse; Sodium Chloride 0.9%  Flush; Iso-Osmotic Sodium Chloride; Fluticasone-Salmeterol (250/50); D5W; Insulin; Insulin Human Regular; MethylPREDNISolone Sodium Succ; Magnesium Oxide; Potassium Chloride; Captopril; Pantoprazole Sodium; Vial; Miconazole Powder 2%; Influenza Virus Vaccine; Albuterol 0.083% Neb Soln; Atorvastatin; Lansoprazole Oral Disintegrating Tab; Scopolamine Patch; Dextrose 5%; Levofloxacin; Ipratropium Bromide Neb; CefePIME; Docusate Sodium (Liquid); Sodium Polystyrene Sulfonate; PredniSONE; Nephrocaps; PNEUMOcoccal Vac Polyvalent; Cyanocobalamin; FoLIC Acid
- Procedures performed: Temporary tracheostomy; Percutaneous [endoscopic] gastrostomy [PEG]; Diagnostic ultrasound of heart; Enteral infusion of concentrated nutritional substances; Hemodialysis; Bronchoscopy through artificial stoma; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning: 

1. **Current Diagnoses**: The patient has been diagnosed with "Other and unspecified hyperlipidemia." This diagnosis is a direct indication of a lipid metabolism disorder, which falls under the category of Disorders of Lipid Metabolism. The presence of this diagnosis strongly suggests that the patient has an ongoing issue with lipid metabolism that is likely to be monitored and managed in future visits.

2. **Medications**: The patient is prescribed Atorvastatin, which is a statin used to manage cholesterol levels. While the use of statins alone is not sufficient to predict a future diagnosis of lipid disorders, in conjunction with the diagnosis of hyperlipidemia, it indicates that the patient's lipid levels are being actively managed. This further supports the likelihood of a lipid disorder diagnosis in the next visit.

3. **Comorbid Conditions**: The patient has several comorbid conditions, including diabetes mellitus and chronic kidney disease. Both of these conditions are associated with dyslipidemia and can exacerbate lipid metabolism disorders. However, the key factor here is the explicit diagnosis of hyperlipidemia, which is a direct indicator of a lipid disorder.

4. **Procedures**: The procedures performed during this visit, such as hemodialysis, may indirectly relate to the management of lipid levels, especially in the context of chronic kidney disease, but they do not provide direct evidence of a lipid disorder.

5. **Conclusion**: Given the explicit diagnosis of "Other and unspecified hyperlipidemia" and the prescription of Atorvastatin, there is strong evidence that the patient has a lipid metabolism disorder that is being actively managed. Therefore, it is reasonable to predict that "Disorders of Lipid Metabolism" will be present as a diagnosis in the patient's next hospital visit. 

Overall, the combination of the current diagnosis and the management plan indicates a high likelihood of a future diagnosis of Disorders of Lipid Metabolism.
```

---

### pair_id=8843

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Aortic valve disorders; Cellulitis and abscess of trunk; Chronic lymphoid leukemia, without mention of having achieved remission; Acidosis; Cellulitis and abscess of leg, except foot; Other postoperative infection; Other and unspecified infection due to central venous catheter; Coronary atherosclerosis of native coronary artery; Atrial fibrillation; Unspecified essential hypertension; Other iatrogenic hypotension; Other specified procedures as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure; Enlargement of lymph nodes; Methicillin susceptible Staphylococcus aureus in conditions classified elsewhere and of unspecified site; Pure hypercholesterolemia; Hip joint replacement; Asthma, unspecified type, unspecified
- Medications prescribed: Metoprolol; SW; Dextrose 50%; Docusate Sodium; Ranitidine; Aspirin EC; Acetaminophen; Qvar; Amiodarone; Warfarin; Iron Polysaccharides Complex; Psyllium Wafer; Levofloxacin; Magnesium Sulfate; Furosemide; Iso-Osmotic Dextrose; Vancomycin; CeftazIDIME; Bisacodyl; Heparin Flush PICC (100 units/ml); Potassium Chloride; Senna; D5W; Oxycodone-Acetaminophen; Metoclopramide; Insulin Human Regular; Nitroglycerin; Morphine Sulfate; Calcium Gluconate; Albumin 5% (25g / 500mL); Influenza Virus Vaccine; Captopril; Insulin; Sodium Chloride 0.9%  Flush; Atorvastatin; Milk of Magnesia; PNEUMOcoccal Vac Polyvalent; Cyclobenzaprine HCl; Amlodipine; Triamterene; Carvedilol; 1/2 NS; Propofol; Aspirin; Glycopyrrolate; Docusate Sodium (Liquid); Neostigmine; LR; Chlorhexidine Gluconate 0.12% Oral Rinse; Sucralfate
- Procedures performed: Open and other replacement of aortic valve with tissue graft; Double internal mammary-coronary artery bypass; Excisional debridement of wound, infection, or burn; Extracorporeal circulation auxiliary to open heart surgery; Venous catheterization, not elsewhere classified; Diagnostic ultrasound of heart; Other incision with drainage of skin and subcutaneous tissue
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning: 

Upon reviewing the patient's current hospital visit record, there is explicit evidence of a lipid disorder present. The diagnosis of "Pure hypercholesterolemia" is clearly stated in the list of diagnoses made during this visit. This diagnosis directly falls under the category of "Disorders of Lipid Metabolism," which includes conditions such as hypercholesterolemia, hyperlipidemia, and related lipid abnormalities.

The presence of hypercholesterolemia indicates that the patient has an ongoing lipid metabolism disorder that is likely to be actively managed. Given that this diagnosis is already established, it is reasonable to predict that it will be coded again in the patient's next hospital visit. 

Additionally, the patient is prescribed Atorvastatin, a medication commonly used to manage cholesterol levels, which further supports the likelihood of continued management of this lipid disorder. The combination of an existing diagnosis of hypercholesterolemia and the use of a statin for treatment strongly suggests that the patient will have "Disorders of Lipid Metabolism" diagnosed again in the future.

In summary, the explicit diagnosis of hypercholesterolemia and the ongoing management with Atorvastatin provide strong evidence that "Disorders of Lipid Metabolism" will be present in the patient's next hospital visit.
```

---

### pair_id=9503

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Septicemia due to pseudomonas; Pressure ulcer, stage IV; Urinary tract infection, site not specified; Sepsis; Neurogenic bladder NOS; Multiple sclerosis; Anemia, unspecified; Dysthymic disorder; Pure hypercholesterolemia; Personal history of malignant neoplasm of esophagus; Autonomic dysreflexia; Streptococcal septicemia; Calculus of kidney; Hyperpotassemia; Pressure ulcer, lower back; Hypopotassemia; Disorders of phosphorus metabolism; Gastrostomy status; Malnutrition of moderate degree
- Medications prescribed: Sterile Water; Pantoprazole; Potassium Chloride; Tobramycin Sulfate; 5% Dextrose; 0.9% Sodium Chloride (Mini Bag Plus); Potassium Chloride (Powder); Meropenem; Paroxetine; Gabapentin; HYDROmorphone (Dilaudid); Ferrous Sulfate; Prochlorperazine; Fentanyl Patch; Acetaminophen; Ondansetron; Vitamin D; Lorazepam; Docusate Sodium (Liquid); Midodrine; Atorvastatin; Lidocaine 5% Patch; Bisacodyl; Heparin; Influenza Virus Vaccine; Senna; Vial; Iso-Osmotic Dextrose; Vancomycin; CefTAZidime; 0.9% Sodium Chloride; Daptomycin; Heparin Flush (10 units/ml); Sodium Chloride 0.9%  Flush; Vitamin A; Zinc Sulfate; Ferrous Sulfate (Liquid); Ascorbic Acid (Liquid); Metoclopramide; Potassium Phosphate; Neutra-Phos; Sodium Polystyrene Sulfonate
- Procedures performed: Venous catheterization, not elsewhere classified; Replacement of nephrostomy tube; Percutaneous pyelogram; Enteral infusion of concentrated nutritional substances
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning: The patient's current visit record includes a diagnosis of "Pure hypercholesterolemia." This is a clear and explicit indication of a lipid metabolism disorder, which falls under the definition of "Disorders of Lipid Metabolism." The presence of this diagnosis suggests that the patient has an ongoing issue with lipid metabolism that is likely to be monitored and managed in future visits.

Additionally, the patient is prescribed Atorvastatin, a medication commonly used to manage cholesterol levels, which further supports the likelihood of a lipid disorder being actively managed. The combination of the diagnosis of hypercholesterolemia and the prescription of a statin indicates that the patient's lipid levels are being addressed, reinforcing the expectation that this condition will be coded in the next hospital visit.

Given these factors, there is strong evidence that "Disorders of Lipid Metabolism" will be present as a diagnosis in the patient's next hospital visit.
```

---

### pair_id=10330

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Drug withdrawal; Alkalosis; Opioid type dependence, continuous; Cocaine abuse, unspecified; Chronic hepatitis C without mention of hepatic coma; Bipolar I disorder, most recent episode (or current) unspecified; Lack of housing; Alcohol abuse, unspecified; Unspecified nonpsychotic mental disorder; Sedative, hypnotic or anxiolytic dependence, continuous; Drug-induced mood disorder
- Medications prescribed: Methadone; Diazepam; Multivitamins; FoLIC Acid; Thiamine; Potassium Chloride; 0.9% Sodium Chloride; Calcium Gluconate; Potassium Phosphate; Multivitamin IV; 5% Dextrose; Sodium Chloride 0.9%  Flush; Docusate Sodium; Senna; Ondansetron; Acetaminophen; Quetiapine Fumarate; Ibuprofen; DiCYCLOmine; Methocarbamol; bismuth subsalicy; Artificial Tears
- Procedures performed: None recorded
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" present or actively managed. The diagnoses made during this visit include various substance dependencies, chronic hepatitis C, and mental health disorders, but none of these directly indicate a lipid metabolism disorder such as hypercholesterolemia or hyperlipidemia.

The medications prescribed do not include any lipid-lowering agents (e.g., statins or fibrates) that would suggest an ongoing management of a lipid disorder. The absence of any mention of lipid levels, lipid profiles, or specific diagnoses related to lipid metabolism further supports the conclusion that there is no current evidence of a lipid disorder.

Additionally, while the patient may have risk factors associated with lipid disorders (such as chronic hepatitis C and substance abuse), these alone do not warrant a diagnosis of "Disorders of Lipid Metabolism" without clear evidence of such a condition being present or treated.

In summary, since there is no strong and explicit evidence of a lipid disorder in the current visit record, the prediction is that "Disorders of Lipid Metabolism" will not be diagnosed in the patient's next hospital visit.
```

---

### pair_id=10771

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Polycystic kidney, autosomal dominant; Secondary hyperparathyroidism (of renal origin); Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; Hyposmolality and/or hyponatremia; Congenital cystic disease of liver; Other ascites; Umbilical hernia without mention of obstruction or gangrene; End stage renal disease; Cirrhosis of liver without mention of alcohol; Anemia in chronic kidney disease; Volume depletion, unspecified; Other iatrogenic hypotension; Kidney dialysis as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure
- Medications prescribed: Sodium Chloride; 0.9% Sodium Chloride; Calcium Carbonate; 1/2 NS; Omeprazole; Albumin 5% (25g / 500mL); Levofloxacin; Heparin Flush (5000 Units/mL); Sodium Chloride 0.9%  Flush; Midodrine; Levothyroxine Sodium; Potassium Chloride; Magnesium Sulfate; Lidocaine 1%; Neutra-Phos; Albumin, Human; Bag; HYDROmorphone (Dilaudid); Ondansetron; CefazoLIN; Acetaminophen; D5 1/2NS; NIFEdipine CR; Metoprolol Tartrate; sevelamer HYDROCHLORIDE; Nephrocaps; Docusate Sodium; Heparin; Bisacodyl; Albumin 25% (12.5g / 50mL); Senna
- Procedures performed: Bilateral nephrectomy; Other open umbilical herniorrhaphy
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: 

Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" being diagnosed or actively managed. The diagnoses made during this visit include several serious conditions such as end-stage renal disease, cirrhosis of the liver, and chronic kidney disease, but none of these directly indicate a lipid metabolism disorder.

1. **Diagnoses**: The patient has multiple significant health issues, including chronic kidney disease and liver cirrhosis. While these conditions can influence lipid metabolism, they do not inherently indicate a diagnosis of a lipid disorder such as hyperlipidemia or hypercholesterolemia. There is no mention of any lipid profile abnormalities or specific lipid disorders in the diagnoses.

2. **Medications**: The medications prescribed do not include any that are typically used to manage lipid disorders, such as statins or fibrates. While the patient is on medications like Metoprolol and Nifedipine, which are used for cardiovascular conditions, these alone do not provide evidence of a lipid disorder. The presence of medications for managing other conditions (e.g., renal and hepatic issues) does not imply an active management of lipid levels.

3. **Procedures**: The procedures performed, including bilateral nephrectomy and umbilical herniorrhaphy, are not related to lipid metabolism. They focus on addressing the patient's renal and hernia issues, which do not provide any direct evidence of lipid disorders.

4. **Risk Factors**: Although the patient has chronic kidney disease and cirrhosis, which can be associated with dyslipidemia, the absence of a documented lipid disorder diagnosis or management plan means that we cannot predict a future diagnosis of "Disorders of Lipid Metabolism." The presence of these comorbidities does not automatically lead to a diagnosis of lipid disorders.

In conclusion, without explicit evidence of a lipid disorder diagnosis or management in the current visit record, the prediction is that "Disorders of Lipid Metabolism" will not be present in the patient's next hospital visit.
```

---

## Mode `coagent`

- Results: `data/outputs/mimiciii/llm_coagent_results.csv`
- Raw JSON per row: `data/outputs/mimiciii/raw_llm_responses/coagent/`
- Rendered prompts (if present): `data/outputs/mimiciii/prompts_used/coagent/prompt_<pair_id>.txt`

### pair_id=25

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease; End stage renal disease; Other encephalopathy; Chronic glomerulonephritis in diseases classified elsewhere; Urinary tract infection, site not specified; Acidosis; Unspecified iridocyclitis; Acquired hemolytic anemia, unspecified; Systemic lupus erythematosus; Personal history of venous thrombosis and embolism; Long-term (current) use of anticoagulants; Swelling, mass, or lump in head and neck; Hyperpotassemia; Lump or mass in breast; Thrombocytopenia, unspecified; Hypocalcemia; Disorders of phosphorus metabolism
- Medications prescribed: Ciprofloxacin HCl; D5W; Labetalol; Morphine Sulfate; Prochlorperazine; NIFEdipine CR; HydrALAzine; Calcium Gluconate; Ondansetron; Sodium Bicarbonate; PredniSONE; LeVETiracetam; Guaifenesin; Sodium Polystyrene Sulfonate; Bisacodyl; Docusate Sodium; Senna; Warfarin; Lactulose; Aliskiren; Clonidine Patch 0.3 mg/24 hr; Furosemide; Heparin Flush (10 units/ml); Alteplase; Magnesium Sulfate; Lorazepam; SW; Ciprofloxacin IV
- Procedures performed: None recorded
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" present. The diagnoses made during this visit include several serious conditions such as hypertensive chronic kidney disease, end-stage renal disease, and systemic lupus erythematosus, but none of these directly indicate a lipid metabolism disorder like hyperlipidemia or hypercholesterolemia.

The medications prescribed do not include any lipid-lowering agents, such as statins or other medications typically used to manage lipid disorders. While the patient is on a variety of medications for other conditions, none are specifically aimed at addressing lipid metabolism issues. 

Additionally, the absence of any historical diagnoses related to lipid metabolism disorders in the current visit record further supports the prediction. There are no indications of previous hyperlipidemia or related conditions that would suggest an ongoing management of lipid disorders.

Given these observations, the criteria for predicting a future diagnosis of "Disorders of Lipid Metabolism" are not met, leading to the conclusion that it is unlikely this diagnosis will be coded in the patient's next hospital visit.
```

---

### pair_id=648

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `fallback`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hypoxemia; Multiple myeloma, without mention of having achieved remission; Peripheral stem cells replaced by transplant; Pneumonia, organism unspecified; [ICD9-DX:2554]; Antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use; Other postablative hypothyroidism
- Medications prescribed: Hydrocortisone Na Succ.; Hydrocortisone; Neutra-Phos; Furosemide; Ipratropium Bromide Neb; Albuterol 0.083% Neb Soln; Sulfameth/Trimethoprim DS; Insulin; Levofloxacin; Sodium Chloride 0.9%  Flush; SW; Testosterone 2.5mg Patch; Potassium Chloride Replacement (Oncology); Senna; Docusate Sodium; NS; Magnesium Sulfate; Potassium Phosphate; Levothyroxine Sodium; Heparin; Heparin Sodium; D5W; Sodium Bicarbonate; Sulfameth/Trimethoprim; Acetylcysteine 20%; Pantoprazole; Heparin Flush PICC (100 units/ml); Heparin Flush (10 units/ml); PredniSONE
- Procedures performed: Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
**Prediction:** No

**Reasoning:** 

Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" present. The diagnoses made during this visit include hypoxemia, multiple myeloma, pneumonia, and other conditions, but none of these directly indicate a lipid metabolism disorder such as hyperlipidemia or hypercholesterolemia.

1. **Diagnosis Review**: The diagnoses listed do not include any terms or codes that are associated with lipid metabolism disorders. There is no mention of hyperlipidemia, hypercholesterolemia, or any related conditions.

2. **Medication Analysis**: The medications prescribed do not include any lipid-lowering agents such as statins (e.g., Atorvastatin) or other medications typically used to manage lipid disorders. While the patient is on a variety of medications, none are specifically aimed at addressing lipid metabolism.

3. **Contextual Understanding of Conditions**: The patient's current conditions, including multiple myeloma and pneumonia, do not inherently suggest the presence of lipid metabolism disorders. While chronic conditions can coexist with lipid disorders, there is no indication in this record that the patient has a history of lipid abnormalities or is being treated for such.

4. **Historical Data**: There is no information provided about the patient's previous medical history that would suggest a prior diagnosis of lipid metabolism disorders. Without any historical context indicating previous lipid issues, it is difficult to predict a future diagnosis.

5. **Holistic Patient Assessment**: The overall assessment of the patient's health status does not reveal any potential issues with lipid metabolism. The absence of relevant diagnoses and medications leads to the conclusion that there is no current management or indication of a lipid disorder.

In summary, based on the current visit record, there is no strong or explicit evidence to suggest that "Disorders of Lipid Metabolism" will be diagnosed in the patient's next hospital visit. Therefore, the prediction is "No."
```

---

### pair_id=2081

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `fallback`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Lumbosacral spondylosis without myelopathy; [ICD9-DX:5185]; Defibrination syndrome; Scoliosis [and kyphoscoliosis], idiopathic; Coronary atherosclerosis of native coronary artery; Unspecified essential hypertension; Unspecified acquired hypothyroidism; Pure hypercholesterolemia; Aortocoronary bypass status
- Medications prescribed: None recorded
- Procedures performed: Lumbar and lumbosacral fusion of the anterior column, posterior technique; Other exploration and decompression of spinal canal; Continuous invasive mechanical ventilation for less than 96 consecutive hours; Insertion of endotracheal tube
```

**Model reply** (`raw_response`):

```
**Prediction:** Yes

**Reasoning:** 

Upon reviewing the patient's current hospital visit record, there is strong and explicit evidence of a lipid disorder present. The diagnosis of "Pure hypercholesterolemia" is explicitly noted in the patient's medical record. This diagnosis falls directly under the category of "Disorders of Lipid Metabolism," which includes conditions such as hypercholesterolemia, hyperlipidemia, and related lipid abnormalities.

1. **Diagnosis Review**: The presence of "Pure hypercholesterolemia" is a clear indicator of a lipid metabolism disorder. This diagnosis suggests that the patient has elevated cholesterol levels, which is a direct manifestation of a disorder of lipid metabolism.

2. **Medication Analysis**: Although no medications are recorded in the current visit, the diagnosis itself is sufficient to indicate that the patient has a lipid disorder. The absence of lipid-lowering medications does not negate the diagnosis of hypercholesterolemia.

3. **Contextual Understanding of Conditions**: The patient also has comorbid conditions such as coronary atherosclerosis and unspecified essential hypertension, which are often associated with lipid metabolism disorders. However, the key factor here is the explicit diagnosis of hypercholesterolemia.

4. **Historical Data**: The current visit record does not indicate any previous diagnoses of lipid disorders, but the current diagnosis of hypercholesterolemia is sufficient to predict that this condition will likely be coded again in the next hospital visit.

5. **Holistic Patient Assessment**: The combination of the explicit diagnosis of hypercholesterolemia and the patient's cardiovascular conditions suggests ongoing management and monitoring of lipid levels, which further supports the likelihood of a lipid disorder diagnosis in future visits.

Given the strong evidence of hypercholesterolemia, it is reasonable to predict that "Disorders of Lipid Metabolism" will be present in the patient's next hospital visit.
```

---

### pair_id=4305

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Methicillin susceptible Staphylococcus aureus septicemia; Intraspinal abscess; Acute respiratory failure; Acute osteomyelitis, other specified sites; Retention of urine, unspecified; Chronic hepatitis C without mention of hepatic coma; Urinary tract infection, site not specified; Cocaine abuse, unspecified; Severe sepsis; Intervertebral disc disorder with myelopathy, cervical region; Dysthymic disorder; Anemia of other chronic disease
- Medications prescribed: Sodium Chloride 0.9%  Flush; Pantoprazole Sodium; Vial; Heparin; Iso-Osmotic Dextrose; Ampicillin Sodium; Vancomycin HCl; NS (Mini Bag Plus); Morphine Sulfate; Acyclovir; Potassium Chl 20 mEq / 1000 mL D5 1/2 NS; D5W; Potassium Chloride; Midazolam HCl; CefTRIAXone; SW; NS; Nafcillin; Docusate Sodium (Liquid); Bisacodyl; Acetaminophen (Liquid); Dexamethasone; Oxycodone-Acetaminophen Elixir; Oxycodone Liquid; Propofol; Albuterol; Insulin; Potassium Chl 40 mEq / 1000 mL D5 1/2 NS; Albuterol 0.083% Neb Soln; Neutra-Phos; Heparin Flush PICC (100 units/ml); Lactulose; Oxycodone (Sustained Release); OxycodONE (Immediate Release); Alteplase (Catheter Clearance); Ciprofloxacin HCl; Ibuprofen; Acetaminophen; Docusate Sodium; Pantoprazole; Hepatitis B Vaccine
- Procedures performed: Other exploration and decompression of spinal canal; Continuous invasive mechanical ventilation for less than 96 consecutive hours; Insertion of endotracheal tube; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" present or actively managed. The diagnoses made during this visit include serious conditions such as septicemia, acute respiratory failure, and chronic hepatitis C, but none of these directly indicate a lipid metabolism disorder like hyperlipidemia or hypercholesterolemia.

The medications prescribed do not include any lipid-lowering agents such as statins or other medications typically associated with the management of lipid disorders. While the patient is on a variety of medications for other serious conditions, the absence of any specific treatment or diagnosis related to lipid metabolism is a critical factor in this analysis.

Additionally, the procedures performed during this visit do not suggest any intervention or assessment related to lipid metabolism. The patient's medical history does not indicate any previous diagnoses of lipid disorders, nor is there any mention of ongoing management for such conditions.

Given these observations, the criteria for predicting a future diagnosis of "Disorders of Lipid Metabolism" are not met. Therefore, the prediction is "No."
```

---

### pair_id=5346

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Infection and inflammatory reaction due to other vascular device, implant, and graft; Unspecified septicemia; Acute posthemorrhagic anemia; Thrombocytopenia, unspecified; Angiodysplasia of intestine with hemorrhage; Atrial fibrillation; Congestive heart failure, unspecified; Aortocoronary bypass status; Cardiac pacemaker in situ
- Medications prescribed: Vancomycin HCl; Insulin; Epoetin Alfa; Vial; D5W; Potassium Chloride; Bumetanide; Furosemide; Bivalirudin; Lorazepam; Gentamicin; Isotonic Sodium Chloride; Magnesium Sulfate; Magnesium Oxide; Iso-Osmotic Dextrose; Aspirin EC; Meropenem; NS; SW; Dopamine HCl; Adenosine; Ibutilide Fumarate; Sarna Lotion; traZODONE HCl; Warfarin; Imipenem-Cilastatin; Sertraline HCl; Carvedilol; Enalapril Maleate; Ciprofloxacin; Metronidazole; Miconazole Powder 2%; Docusate Sodium; Senna; Atorvastatin; Amiodarone HCl; Acetaminophen; Pantoprazole; Aluminum-Magnesium Hydroxide; Golytely; Potassium Phosphate; Ranitidine; DopAmine; Diphenhydramine HCl; Linezolid
- Procedures performed: Other endoscopy of small intestine; Endoscopic control of gastric or duodenal bleeding; Colonoscopy; Other electric countershock of heart; Diagnostic ultrasound of heart; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" that would likely lead to a diagnosis in the next hospital visit. 

1. **Diagnoses Made**: The patient has several serious conditions, including infections, septicemia, anemia, and heart-related issues. However, none of these diagnoses directly indicate a lipid metabolism disorder such as hyperlipidemia or hypercholesterolemia.

2. **Medication Analysis**: The patient is prescribed Atorvastatin, which is a lipid-lowering medication. However, the mere presence of a statin does not provide sufficient evidence to predict a future diagnosis of a lipid disorder. The use of statins alone, without a documented diagnosis of a lipid disorder, does not meet the criteria for a "Yes" prediction.

3. **Contextual Understanding of Conditions**: While the patient has comorbid conditions such as atrial fibrillation and congestive heart failure, these conditions are not directly indicative of a lipid metabolism disorder. They may be associated with cardiovascular risk factors but do not confirm the presence of a lipid disorder.

4. **Historical Data**: There is no mention of previous diagnoses related to lipid metabolism disorders in the current visit record. Without historical context indicating a known lipid disorder, it is difficult to predict that one will be diagnosed in the future.

5. **Holistic Patient Assessment**: The overall assessment of the patient's health status does not reveal any indicators of lipid metabolism issues. The focus of the current visit appears to be on acute medical conditions rather than chronic lipid disorders.

6. **Refined Criteria Application**: The refined criteria emphasize the need for explicit evidence of lipid disorders. In this case, while the patient is on a statin, there is no documented diagnosis of hyperlipidemia or related conditions, which leads to the conclusion that a future diagnosis is unlikely.

In summary, despite the patient's complex medical history and the use of a statin, there is insufficient evidence to support a prediction of "Disorders of Lipid Metabolism" being diagnosed in the next hospital visit. Therefore, the prediction is "No."
```

---

### pair_id=5618

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Intracerebral hemorrhage; Pneumonia, organism unspecified; Other vascular complications of medical care, not elsewhere classified; Other convulsions; Chronic airway obstruction, not elsewhere classified; Hypopotassemia; Other musculoskeletal symptoms referable to limbs; Unspecified essential hypertension; Pure hypercholesterolemia; Other specified disease of white blood cells; Other specified anemias; Unspecified diseases of blood and blood-forming organs; Lumbago; Personal history of other diseases of circulatory system
- Medications prescribed: NS; Phenytoin Sodium; Morphine Sulfate; Metoprolol; Zolpidem Tartrate; Fluocinonide 0.05% Cream; Insulin; Enalapril Maleate; Diltiazem; NS (Glass Bottle); Lorazepam; Levetiracetam; Clonidine HCl; Vancomycin HCl; Iso-Osmotic Dextrose; HydrOXYzine HCl; Aspirin; Cyclobenzaprine HCl; Verapamil HCl; Amlodipine; Pantoprazole; Haloperidol; Sodium Chloride 0.9%  Flush; Senna; HydrALAZINE HCl; Heparin; Heparin Flush CVL  (100 units/ml); Potassium Chloride; Ibuprofen Suspension; Lansoprazole Oral Suspension; Dextrose 5%; Levofloxacin; NiCARdipine IV; Propofol; Clonidine TTS 2 Patch; Docusate Sodium (Liquid); Calcium Gluconate; Oxycodone-Acetaminophen Elixir; Dexamethasone; Mannitol 20%; Soln.; Fentanyl Citrate; Acetaminophen; Vial; Pantoprazole Sodium; Alteplase (Catheter Clearance); Neutra-Phos; Clonidine TTS 1 Patch; Magnesium Sulfate; SW
- Procedures performed: Continuous invasive mechanical ventilation for 96 consecutive hours or more; Enteral infusion of concentrated nutritional substances; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning: 

1. **Diagnosis Review**: The patient's current visit record includes a diagnosis of "Pure hypercholesterolemia." This is a direct indication of a lipid metabolism disorder, as hypercholesterolemia falls under the category of Disorders of Lipid Metabolism. The presence of this diagnosis is a strong indicator that the patient has an existing lipid disorder.

2. **Medication Analysis**: While the medication list does not explicitly include lipid-lowering agents such as statins, the diagnosis of hypercholesterolemia itself is sufficient to suggest that the patient may be under management for this condition, which could include lifestyle modifications or future prescriptions for lipid-lowering medications.

3. **Contextual Understanding of Conditions**: The patient has multiple comorbid conditions, including hypertension and other vascular complications, which are often associated with lipid metabolism disorders. However, the key factor here is the explicit diagnosis of hypercholesterolemia.

4. **Historical Data**: The current visit record does not indicate any previous diagnoses of lipid disorders, but the presence of pure hypercholesterolemia in this visit is critical. It suggests that the patient has been identified as having a lipid metabolism issue during this hospitalization.

5. **Holistic Patient Assessment**: The combination of the diagnosis of pure hypercholesterolemia and the patient's overall health status indicates that there is an ongoing concern regarding lipid metabolism. This diagnosis is likely to be coded in future visits as it reflects a chronic condition that requires monitoring and management.

6. **Avoiding Overlooking Indicators**: The diagnosis of hypercholesterolemia is a clear and explicit indicator of a lipid metabolism disorder, which aligns with the refined criteria that emphasize the importance of comprehensive diagnosis review.

In conclusion, the presence of "Pure hypercholesterolemia" in the current visit record provides strong evidence that the patient will likely have a diagnosis of "Disorders of Lipid Metabolism" in their next hospital visit.
```

---

### pair_id=6816

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `fallback`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Hyperpotassemia; Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled; Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; End stage renal disease; Other chest pain; Other specified cardiac dysrhythmias; Congestive heart failure, unspecified; Diastolic heart failure, unspecified; Pure hypercholesterolemia; Coronary atherosclerosis of native coronary artery; Diarrhea; Aortocoronary bypass status; Percutaneous transluminal coronary angioplasty status
- Medications prescribed: Morphine Sulfate; Heparin; Aspirin; Sevelamer; Isosorbide Mononitrate (Extended Release); Atorvastatin; Metoprolol; Insulin; Acetaminophen; Amlodipine; D5W; Heparin Sodium; Nitroglycerin; Sodium Chloride 0.9%  Flush
- Procedures performed: Hemodialysis
```

**Model reply** (`raw_response`):

```
**Prediction:** Yes

**Reasoning:** 

1. **Diagnosis Review**: The patient's current visit record includes a diagnosis of "Pure hypercholesterolemia." This is a direct indication of a lipid metabolism disorder, as it falls under the category of disorders of lipid metabolism defined in the target definition.

2. **Medication Analysis**: The patient has been prescribed Atorvastatin, which is a statin used to manage cholesterol levels. The presence of this medication further supports the diagnosis of a lipid disorder, as it indicates active management of the patient's lipid levels.

3. **Contextual Understanding of Conditions**: The patient has multiple chronic conditions, including diabetes with renal manifestations and congestive heart failure. While these conditions are significant, they do not negate the presence of a lipid metabolism disorder. In fact, they can often coexist with lipid disorders, making it crucial to consider the hypercholesterolemia diagnosis.

4. **Holistic Patient Assessment**: The combination of the diagnosis of pure hypercholesterolemia and the prescription of a lipid-lowering agent (Atorvastatin) provides strong evidence that the patient is currently being treated for a lipid metabolism disorder. This suggests that the condition is actively managed and likely to be coded in future visits.

5. **Refined Criteria Application**: The refined criteria emphasize the importance of comprehensive diagnosis review and medication analysis. The explicit diagnosis of hypercholesterolemia and the use of Atorvastatin align perfectly with these criteria, indicating a clear and ongoing management of a lipid disorder.

Given the strong evidence from the current visit record, including the diagnosis of pure hypercholesterolemia and the prescription of Atorvastatin, it is reasonable to predict that "Disorders of Lipid Metabolism" will be present as a diagnosis in the patient's next hospital visit.
```

---

### pair_id=8330

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Cerebral embolism with cerebral infarction; End stage renal disease; Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; Hemiplegia, unspecified, affecting unspecified side; Pneumonitis due to inhalation of food or vomitus; Acute respiratory failure; Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled; Aortic valve disorders; Mitral valve disorders; Chronic airway obstruction, not elsewhere classified; Anemia in chronic kidney disease; Other and unspecified hyperlipidemia; Personal history of malignant neoplasm of prostate; Unspecified sleep apnea; Aphasia; Hypotension, unspecified; [ICD9-DX:7806]; Other and unspecified complications of medical care, not elsewhere classified
- Medications prescribed: Bisacodyl; Allopurinol; Heparin; Lanthanum; Senna; NS; Aspirin; Haloperidol; MetRONIDAZOLE (FLagyl); Acetaminophen; Famotidine; Fluticasone Propionate 110mcg; Iso-Osmotic Dextrose; Vancomycin; Ipratropium Bromide MDI; Albuterol; Fentanyl Citrate; Morphine Sulfate; Chlorhexidine Gluconate 0.12% Oral Rinse; Sodium Chloride 0.9%  Flush; Iso-Osmotic Sodium Chloride; Fluticasone-Salmeterol (250/50); D5W; Insulin; Insulin Human Regular; MethylPREDNISolone Sodium Succ; Magnesium Oxide; Potassium Chloride; Captopril; Pantoprazole Sodium; Vial; Miconazole Powder 2%; Influenza Virus Vaccine; Albuterol 0.083% Neb Soln; Atorvastatin; Lansoprazole Oral Disintegrating Tab; Scopolamine Patch; Dextrose 5%; Levofloxacin; Ipratropium Bromide Neb; CefePIME; Docusate Sodium (Liquid); Sodium Polystyrene Sulfonate; PredniSONE; Nephrocaps; PNEUMOcoccal Vac Polyvalent; Cyanocobalamin; FoLIC Acid
- Procedures performed: Temporary tracheostomy; Percutaneous [endoscopic] gastrostomy [PEG]; Diagnostic ultrasound of heart; Enteral infusion of concentrated nutritional substances; Hemodialysis; Bronchoscopy through artificial stoma; Venous catheterization, not elsewhere classified
```

**Model reply** (`raw_response`):

```
Prediction: Yes

Reasoning: 

1. **Current Diagnoses**: The patient's current visit record includes "Other and unspecified hyperlipidemia." This diagnosis is a direct indication of a lipid metabolism disorder, as it falls under the category of lipid abnormalities. The presence of this diagnosis strongly suggests that the patient has an ongoing issue with lipid metabolism.

2. **Medication Profile**: The patient is prescribed Atorvastatin, which is a statin used to manage cholesterol levels. While the use of statins alone is not sufficient to predict a future diagnosis of lipid disorders, in conjunction with the diagnosis of hyperlipidemia, it indicates that the patient is actively being treated for a lipid metabolism disorder.

3. **Comorbid Conditions**: The patient has several comorbid conditions, including diabetes and chronic kidney disease, which are often associated with dyslipidemia. However, the presence of these conditions alone does not warrant a prediction of lipid disorders; it is the explicit diagnosis of hyperlipidemia that is critical.

4. **Procedures and Overall Health Context**: The procedures performed, such as hemodialysis, may indirectly relate to the management of lipid levels, especially in patients with chronic kidney disease. However, the key factor remains the explicit diagnosis of hyperlipidemia.

5. **Refined Criteria Application**: The refined criteria emphasize the importance of comprehensive diagnosis review and medication analysis. The diagnosis of "Other and unspecified hyperlipidemia" is a clear indicator of a lipid metabolism disorder, and the prescribed Atorvastatin supports this diagnosis.

In conclusion, the combination of the explicit diagnosis of hyperlipidemia and the ongoing management with Atorvastatin provides strong evidence that "Disorders of Lipid Metabolism" will be present in the patient's next hospital visit.
```

---

### pair_id=8843

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `fallback`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Aortic valve disorders; Cellulitis and abscess of trunk; Chronic lymphoid leukemia, without mention of having achieved remission; Acidosis; Cellulitis and abscess of leg, except foot; Other postoperative infection; Other and unspecified infection due to central venous catheter; Coronary atherosclerosis of native coronary artery; Atrial fibrillation; Unspecified essential hypertension; Other iatrogenic hypotension; Other specified procedures as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure; Enlargement of lymph nodes; Methicillin susceptible Staphylococcus aureus in conditions classified elsewhere and of unspecified site; Pure hypercholesterolemia; Hip joint replacement; Asthma, unspecified type, unspecified
- Medications prescribed: Metoprolol; SW; Dextrose 50%; Docusate Sodium; Ranitidine; Aspirin EC; Acetaminophen; Qvar; Amiodarone; Warfarin; Iron Polysaccharides Complex; Psyllium Wafer; Levofloxacin; Magnesium Sulfate; Furosemide; Iso-Osmotic Dextrose; Vancomycin; CeftazIDIME; Bisacodyl; Heparin Flush PICC (100 units/ml); Potassium Chloride; Senna; D5W; Oxycodone-Acetaminophen; Metoclopramide; Insulin Human Regular; Nitroglycerin; Morphine Sulfate; Calcium Gluconate; Albumin 5% (25g / 500mL); Influenza Virus Vaccine; Captopril; Insulin; Sodium Chloride 0.9%  Flush; Atorvastatin; Milk of Magnesia; PNEUMOcoccal Vac Polyvalent; Cyclobenzaprine HCl; Amlodipine; Triamterene; Carvedilol; 1/2 NS; Propofol; Aspirin; Glycopyrrolate; Docusate Sodium (Liquid); Neostigmine; LR; Chlorhexidine Gluconate 0.12% Oral Rinse; Sucralfate
- Procedures performed: Open and other replacement of aortic valve with tissue graft; Double internal mammary-coronary artery bypass; Excisional debridement of wound, infection, or burn; Extracorporeal circulation auxiliary to open heart surgery; Venous catheterization, not elsewhere classified; Diagnostic ultrasound of heart; Other incision with drainage of skin and subcutaneous tissue
```

**Model reply** (`raw_response`):

```
**Prediction:** Yes

**Reasoning:** 

1. **Current Diagnoses**: The patient's current visit record includes a diagnosis of "Pure hypercholesterolemia." This is a direct indication of a lipid metabolism disorder, as hypercholesterolemia falls under the category of Disorders of Lipid Metabolism. The presence of this diagnosis is strong evidence that the patient has an existing lipid disorder.

2. **Medications Prescribed**: The patient has been prescribed Atorvastatin, which is a statin used to manage cholesterol levels. While the use of statins alone is not sufficient to predict a future diagnosis, in conjunction with the diagnosis of hypercholesterolemia, it reinforces the management of a lipid disorder.

3. **Comorbid Conditions**: The patient has several comorbid conditions, including coronary atherosclerosis and atrial fibrillation, which are often associated with lipid metabolism disorders. However, the presence of these conditions alone does not warrant a prediction of a lipid disorder diagnosis; it is the explicit diagnosis of hypercholesterolemia that is critical.

4. **Procedures Performed**: The patient underwent significant cardiovascular procedures, including a double internal mammary-coronary artery bypass and open replacement of the aortic valve. These procedures are often related to the management of cardiovascular diseases that can be influenced by lipid levels, but again, they do not directly indicate a new diagnosis of a lipid disorder.

5. **Refined Criteria Application**: The refined criteria emphasize the importance of comprehensive diagnosis review and medication analysis. The explicit diagnosis of hypercholesterolemia and the prescription of a lipid-lowering agent (Atorvastatin) provide strong evidence that the patient is actively being managed for a lipid metabolism disorder.

In conclusion, given the clear diagnosis of hypercholesterolemia and the ongoing management with Atorvastatin, it is highly likely that "Disorders of Lipid Metabolism" will be present as a diagnosis in the patient's next hospital visit.
```

---

### pair_id=9503

- **Ground truth** (`label_lipid_disorder`): 1
- **Parsed prediction**: Yes
- **Verdict**: correct
- **Parser**: `fallback`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Septicemia due to pseudomonas; Pressure ulcer, stage IV; Urinary tract infection, site not specified; Sepsis; Neurogenic bladder NOS; Multiple sclerosis; Anemia, unspecified; Dysthymic disorder; Pure hypercholesterolemia; Personal history of malignant neoplasm of esophagus; Autonomic dysreflexia; Streptococcal septicemia; Calculus of kidney; Hyperpotassemia; Pressure ulcer, lower back; Hypopotassemia; Disorders of phosphorus metabolism; Gastrostomy status; Malnutrition of moderate degree
- Medications prescribed: Sterile Water; Pantoprazole; Potassium Chloride; Tobramycin Sulfate; 5% Dextrose; 0.9% Sodium Chloride (Mini Bag Plus); Potassium Chloride (Powder); Meropenem; Paroxetine; Gabapentin; HYDROmorphone (Dilaudid); Ferrous Sulfate; Prochlorperazine; Fentanyl Patch; Acetaminophen; Ondansetron; Vitamin D; Lorazepam; Docusate Sodium (Liquid); Midodrine; Atorvastatin; Lidocaine 5% Patch; Bisacodyl; Heparin; Influenza Virus Vaccine; Senna; Vial; Iso-Osmotic Dextrose; Vancomycin; CefTAZidime; 0.9% Sodium Chloride; Daptomycin; Heparin Flush (10 units/ml); Sodium Chloride 0.9%  Flush; Vitamin A; Zinc Sulfate; Ferrous Sulfate (Liquid); Ascorbic Acid (Liquid); Metoclopramide; Potassium Phosphate; Neutra-Phos; Sodium Polystyrene Sulfonate
- Procedures performed: Venous catheterization, not elsewhere classified; Replacement of nephrostomy tube; Percutaneous pyelogram; Enteral infusion of concentrated nutritional substances
```

**Model reply** (`raw_response`):

```
**Prediction:** Yes

**Reasoning:** 

1. **Current Diagnoses**: The patient's current visit record includes a diagnosis of "Pure hypercholesterolemia." This is a direct indication of a lipid metabolism disorder, as hypercholesterolemia falls under the umbrella of disorders of lipid metabolism. The presence of this diagnosis is a strong indicator that the patient has an existing lipid disorder.

2. **Medication Profile**: The patient has been prescribed Atorvastatin, which is a statin used to manage cholesterol levels. The use of this medication further supports the diagnosis of a lipid metabolism disorder, as it is specifically indicated for conditions like hypercholesterolemia. While the guidelines state that the use of statins alone is not sufficient to predict a future diagnosis, in this case, it corroborates the existing diagnosis of hypercholesterolemia.

3. **Comorbid Conditions**: The patient has multiple comorbidities, including septicemia and multiple sclerosis, but these do not negate the presence of a lipid disorder. Instead, they may complicate the patient's overall health status. However, the presence of hypercholesterolemia is a clear and explicit indicator of a lipid metabolism disorder.

4. **Refined Criteria Application**: 
   - The comprehensive review of the patient's diagnoses shows a clear indication of hypercholesterolemia.
   - The medication analysis reveals the use of a lipid-lowering agent (Atorvastatin), which is relevant to the management of lipid disorders.
   - The contextual understanding of the patient's health does not detract from the existing diagnosis of a lipid metabolism disorder.

5. **Historical Data**: Although the record does not provide extensive historical data, the current diagnosis of hypercholesterolemia is sufficient to predict that this condition will likely be coded again in the next hospital visit.

In conclusion, the explicit diagnosis of "Pure hypercholesterolemia" and the prescription of Atorvastatin provide strong evidence that "Disorders of Lipid Metabolism" will be present in the patient's next hospital visit. Therefore, the prediction is "Yes."
```

---

### pair_id=10330

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `first_line`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Drug withdrawal; Alkalosis; Opioid type dependence, continuous; Cocaine abuse, unspecified; Chronic hepatitis C without mention of hepatic coma; Bipolar I disorder, most recent episode (or current) unspecified; Lack of housing; Alcohol abuse, unspecified; Unspecified nonpsychotic mental disorder; Sedative, hypnotic or anxiolytic dependence, continuous; Drug-induced mood disorder
- Medications prescribed: Methadone; Diazepam; Multivitamins; FoLIC Acid; Thiamine; Potassium Chloride; 0.9% Sodium Chloride; Calcium Gluconate; Potassium Phosphate; Multivitamin IV; 5% Dextrose; Sodium Chloride 0.9%  Flush; Docusate Sodium; Senna; Ondansetron; Acetaminophen; Quetiapine Fumarate; Ibuprofen; DiCYCLOmine; Methocarbamol; bismuth subsalicy; Artificial Tears
- Procedures performed: None recorded
```

**Model reply** (`raw_response`):

```
Prediction: No

Reasoning: Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" present or actively managed. The diagnoses made during this visit include various substance dependencies, chronic hepatitis C, and mental health disorders, but none of these directly indicate a lipid metabolism disorder such as hyperlipidemia or hypercholesterolemia.

The medications prescribed do not include any lipid-lowering agents, such as statins or other medications typically used to manage lipid disorders. The absence of such medications is a significant indicator that there is no ongoing management or diagnosis of a lipid metabolism disorder.

Additionally, while the patient has several comorbid conditions, including chronic hepatitis C and substance abuse issues, these do not inherently suggest the presence of lipid metabolism disorders. The refined criteria emphasize the importance of identifying explicit diagnoses or management related to lipid metabolism, which is lacking in this case.

Overall, without any direct evidence of a lipid disorder or related management in the current visit record, the prediction is that "Disorders of Lipid Metabolism" will not be coded in the patient's next hospital visit.
```

---

### pair_id=10771

- **Ground truth** (`label_lipid_disorder`): 0
- **Parsed prediction**: No
- **Verdict**: correct
- **Parser**: `fallback`
- **Model**: `gpt-4o-mini-2024-07-18`

**Input narrative** (`narrative_current`):

```
- Diagnoses made: Polycystic kidney, autosomal dominant; Secondary hyperparathyroidism (of renal origin); Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease; Hyposmolality and/or hyponatremia; Congenital cystic disease of liver; Other ascites; Umbilical hernia without mention of obstruction or gangrene; End stage renal disease; Cirrhosis of liver without mention of alcohol; Anemia in chronic kidney disease; Volume depletion, unspecified; Other iatrogenic hypotension; Kidney dialysis as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure
- Medications prescribed: Sodium Chloride; 0.9% Sodium Chloride; Calcium Carbonate; 1/2 NS; Omeprazole; Albumin 5% (25g / 500mL); Levofloxacin; Heparin Flush (5000 Units/mL); Sodium Chloride 0.9%  Flush; Midodrine; Levothyroxine Sodium; Potassium Chloride; Magnesium Sulfate; Lidocaine 1%; Neutra-Phos; Albumin, Human; Bag; HYDROmorphone (Dilaudid); Ondansetron; CefazoLIN; Acetaminophen; D5 1/2NS; NIFEdipine CR; Metoprolol Tartrate; sevelamer HYDROCHLORIDE; Nephrocaps; Docusate Sodium; Heparin; Bisacodyl; Albumin 25% (12.5g / 50mL); Senna
- Procedures performed: Bilateral nephrectomy; Other open umbilical herniorrhaphy
```

**Model reply** (`raw_response`):

```
**Prediction:** No

**Reasoning:** 

Upon reviewing the patient's current hospital visit record, there is no explicit evidence of a "Disorder of Lipid Metabolism" being diagnosed or actively managed. The diagnoses made during this visit include several serious conditions such as end-stage renal disease, cirrhosis of the liver, and chronic kidney disease, but none of these directly indicate a lipid metabolism disorder like hyperlipidemia or hypercholesterolemia.

1. **Diagnosis Review**: The diagnoses listed do not include any terms related to lipid metabolism disorders. There is no mention of hyperlipidemia, hypercholesterolemia, or any other lipid-related conditions. The presence of chronic kidney disease and liver cirrhosis may complicate lipid metabolism, but they do not confirm a diagnosis of lipid disorders.

2. **Medication Analysis**: The medications prescribed do not include any lipid-lowering agents such as statins (e.g., Atorvastatin) or other medications typically used to manage lipid disorders. While the patient is on medications for other conditions, none are specifically aimed at addressing lipid metabolism.

3. **Contextual Understanding of Conditions**: Although the patient has multiple comorbidities, including chronic kidney disease and liver disease, which can influence lipid levels, these conditions alone do not imply a diagnosis of lipid metabolism disorders. The absence of any historical data or current management for lipid disorders further supports this.

4. **Holistic Patient Assessment**: The overall assessment of the patient's health status does not reveal any indicators that would suggest a diagnosis of lipid metabolism disorders. The focus of the current visit appears to be on managing renal and hepatic issues rather than lipid-related concerns.

5. **Refined Criteria Application**: The refined criteria emphasize the importance of explicit evidence of lipid disorders. In this case, there is a lack of such evidence, as the patient has not been diagnosed with or treated for any lipid metabolism issues during this visit.

In conclusion, based on the absence of any direct evidence of a lipid metabolism disorder in the current visit record, I predict that "Disorders of Lipid Metabolism" will not be present as a diagnosis in the patient's next hospital visit.
```

---

